The present invention relates to a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one C-glycoside derivative and at least one emulsifying polymer chosen from polyolefins containing polar portion(s) and amphiphilic polymers comprising at least one acrylamido-2-methylpropanesulfonic acid (AMPS) unit.

This invention relates to functional compositions for use in personal care, household & institutional and pet care applications and which contain cationic hydrophobically modified polysaccharides thereby permitting a reduction in the amount of active ingredient material present in the functional composition over amounts typically found in conventional functional compositions while substantially maintaining the level of performance of the functional composition when compared to the level of performance of the conventional functional composition.

The present invention provides a moisturizing, cosmetic, or anti-wrinkle product comprising at least two hyaluronic acid fractions, or salts thereof, wherein a fraction has an average molecular weight in the range of 8,000-100,000 Da, and a fraction has an average molecular weight in the range of 100,000-500,000 Da.

The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.

Compounds are provided for use with DPP-IV of the formula: Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Methods and compositions for enhancing the activity and/or duration of action of loteprednol etabonate and other soft anti-inflammatory steroids of the haloalkyl 17.alpha.-alkoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-c- arboxylate type and the corresponding .DELTA..sup.1,4-compounds are described. The enhancing agents have the formula: wherein Z.sub.1 is carbonyl, .beta.-hydroxymethylene or methylene; R.sub.2 is H, --OH or --OCOR.sub.3 wherein R.sub.3 is C.sub.1-C.sub.5 alkyl; Y is --OH, --SH or --OCOR.sub.4 wherein R.sub.4 is C.sub.1-C.sub.5 alkyl, cyclopentylethyl or diethylaminoethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated.

The present invention comprises compositions for pharmaceutical drug delivery of an indolone (e.g., ropinirole), or a pharmaceutically acceptable salt thereof. The composition may, for example, be a gel suitable for transdermal application. The compositions of the present invention typically comprise a hydroalcoholic vehicle, one or more antioxidant, and one or more buffering agent, wherein the pH of the gel is usually between about pH 7 and about pH 9. The compositions may include further components, for example, the hydroalcoholic vehicle may further comprise additional solvent(s), antioxidant(s), cosolvent(s), penetration enhancer(s), buffering agent(s), and/or gelling agent(s). The compositions may be used for the treatment of a variety of neurological disorders.

Photostable sunscreen compositions containing at least one cinnamic acid ester UV-B filter and at least one particular s-triazine compound have improved effectiveness with respect to UV-B radiation.

The present disclosure relates to the combination of at least one C-glycoside derivative with at least one additional cosmetic or dermatological ingredient and/or active agent. Disclosed herein are cosmetic and/or dermatological compositions containing such a combination in a physiologically acceptable medium, or alternatively, a cosmetic or dermatological assembly comprising at least two separate compositions respectively containing for one the C-glycoside derivative and for the other the cosmetic or dermatological ingredient and/or active agent. Also disclosed is a cosmetic treatment method for caring for, cleansing and/or making up the skin and/or its appendages using the combination or the composition(s) according to the invention.

The present invention relates to a cosmetic method for improving and/or reinforcing the skin's barrier function comprising at least a step of applying to the skin a composition comprising at least one C-glycoside derivative.

Compositions, for example cosmetic compositions, comprising at least one organic polymer, such as a crosslinked organosoluble polymer, and a mixture of at least two solvents, one of which is volatile and incompatible with the polymer, and the other of which is nonvolatile and compatible with the polymer. These compositions make it possible to form on keratin materials a deposit whose volume increases over time, without the intervention of an external stimulus. These compositions can be, for example, mascaras, lipsticks or anti-wrinkle formulas in the form of a cream or a foundation. The cosmetic treatment processes using these compositions.

Cosmetic/pharmaceutical compositions comprising adapalene dissolved in an aqueous medium with cyclodextrin and/or derivatives thereof, notably as inclusion complexes therewith, are useful as cosmetics and for the therapeutic treatment, e.g., of acne.

A method for treating pain, particularly non-inflammatory musculoskeletal pain such as fibromyalgia, myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.

The invention discloses pharmaceutical compositions containing polydatin or its pharmaceutically acceptable salts with the effect of improving microcirculation, and their application in preparing drugs which can improve microcirculation. The compositions are an non-gastrointestinal injection preparation, the preparation can be an aqueous solution which have pH 7.0-10.0 comprising 5-50% propandiol. The dosage forms of the compositions may be lyophilizing powder injection, oral form, suppository of procto-administration and other forms of administrations comprising unguent, ointment, paste film coating and the like. The compositions may be used to treat and/or prevent diseases related to microcirculation blockage. The unit form may contain 1-1000 mg polydatin or its derivatives. The invention solves the problem of using polydatin to improve microcirculation. The composition of the invention can be used in treating shock, cardiac and cerebrovascular diseases, diseases of sense organs, diabetes complication, vaculitis related to blockage of blood vessel, hemorrhoid related to circulation obstruction, skin injury and burn.

The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2'-methoxy adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds, in particular as analgesic or anti-inflammatory compounds, or as disease modifying antirheumatic drugs (DMARDs), and to methods of preventing, treating or ameliorating pain or inflammation using these compounds.

Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain dialkylhydroxyamine stabilizers, dialkylhydroxylamine stabilizer salts, nitrone stabilizers or amine oxide stabilizers. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

The invention features a method of treating acne by piercing the stratum corneum of skin in need of such treatment with a stratum corneum-piercing device including a microprotrusion member having a skin-contacting surface and plurality of stratum corneum-piercing microprotrusions thereon.

The present invention relates to antiperspirant compositions comprising a cationic hydrophobically modified polymeric gelling agent and an acidic antiperspirant compound. The antiperspirant compositions are transparent, phase stable, non-whitening and non-staining to the skin and clothing following topical application. The present invention also is directed to methods of using the antiperspirant compositions.

The present invention concerns a non-therapeutic method to prevent and/or treat a skin in need of a calmative using a C-glycoside derivative.

Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity, and stability. The formulations, optionally containing non-animal source biologics, may be in the form of lotions, aerosols to provide a spray, or a foam. A non-reactive substrate may be used as a composition carrier. A non-aqueous lotion formulation having improved enzymatic activity is provided. The non-aqueous lotion viscosity is adjusted to achieve high enzymatic activity while maintaining the application benefits of high viscosity non-aqueous lotions. The lotion formulation may be delivered in a patch.

Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.

The invention relates to methods of making films having active ingredients. A film that is substantially free of active ingredient is introduced into a medium comprising an active ingredient. At least a portion of the active ingredient is transferred from the medium to the film. The films can be used in a variety of applications, including oral care, personal care, cleansing and/or home care compositions.

The present invention relates to treatment articles capable of delivering intensive care and overall care simultaneously. The articles comprise a first substrate, a second substrate which substantially covers the first substrate at-use, a first treatment composition and a second treatment composition wherein the delivery of the skin care active to the skin is initiated by the treatment composition. The articles also comprises a first substrate which contains a first treatment composition, a second substrate which substantially cover the first substrate at-use and a treatment composition wherein delivery of the first treatment composition is initiated by the second treatment composition. Preferred articles of the present invention comprise facial treatment masks.

A cosmetic make-up product containing a first and a second composition, the first composition comprising, in a physiologically acceptable medium, dispersed polymer particles surface-stabilized with a stabilizer in a liquid organic phase and a coloring agent, and the second composition comprising a second physiologically acceptable medium.

The present invention relates to a dextran and/or dextran derivative bifunctionalized by at least one imidazolyl radical Im and at least one hydrophobic group Hy, the said radical and the said group being each identical and/or different and grafted or bonded to the dextran and/or dextran derivative via one or more connecting arms R, Ri or Rh and functional groups F, Fi or Fh and the pharmaceutical compositions comprising one of the said dextrans and at least one active principle.

Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H.sub.4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H.sub.4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is --CONH-- or --NR.sup.1CO-- wherein R.sup.1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula:wherein R.sup.2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, --NH-- or D is a bond, --CS-- or --CO--; E is a bond or --NH--; F is a bond, --CO--, --O-- or --SO.sub.2--; and G is lower alkyl, optionally protected amino, --OH, phenyl, R.sup.3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be --CS--, or then A should be lower alkylene, B or E should be --NH-- and F should be --CO--; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

The present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a fatty acid. The composition may further comprise a pharmaceutically active agent. The composition of the invention is also useful for the treatment of a dermatological disorder in a mammal by the topical administration of the composition.

Improvedly effective and photostable sunscreen compositions combine a dibenzoylmethane screening agent and a specific arylalkyl amide or ester compound of the following formulae (I), (II) or (III):

A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.

Methods and materials are provided for induction-maintenance regimens of targeted anti-inflammatory therapies (TATs) for treatment of a variety of diseases and disorders. Preferred embodiments include administration of one or more TATs using an induction regimen comprising a lower dose per administration administered by a more invasive and/or more localized route, followed by administration of one or more TATS using a maintenance regimen, comprising a higher dose per administration administered by a less invasive and/or less localized route.

Pharmaceutical compositions, each consisting of a cell-permeable fusion protein conjugate of a polypeptidic cell-membrane transport moiety and a Clostridium botulinum C3 exotransferase unit, or a functional analog thereof, are provided. The compositions are useful to prevent or inhibit uncontrolled proliferation, spreading, and migration of a metastatic neoplastic cell of a cancer in a mammal. The compositions can each effect or arrest combination of two or more of tumor cell proliferation, migration, angiogenesis, and metalloproteinase secretion.

This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent, such as an opioid antagonist, and a pharmaceutically acceptable salt of an adverse agent, such as an opioid antagonist. The transdermal dosage form allows an effective amount of the active agent, or a pharmaceutically acceptable salt thereof, to be transdermally administered to an animal. The invention further relates to methods for treating or preventing pain in an animal comprising contacting the skin of an animal in need thereof with the transdermal dosage form of the invention for an amount of time sufficient to treat or prevent pain.

The present invention provides an oral skin moisturizer that is readily available to those who are suffering from dry skin, has no side effects, and when orally ingested, enhances the moisture-retaining ability of the skin. The invention also provides food products or the like that contain the oral skin moisturizer. Specifically, the oral skin moisturizer contains, as an active ingredient, a extract of a plant of the genus Lepidium of the family Cruciferae. More specifically, the oral skin moisturizer contains as an active ingredient a extract of maca (Lepidium meyenii Walp). Food products, liquors, functional food products, and pharmaceutical products containing the oral skin moisturizer are also provided.

The invention concerns the use of at least an oligosaccharide comprising 2 to 6 sugars and containing at least 2 galactose units, preferably 2 vicinal end-of-chain galactose motifs, or a plant extract containing same, as a cosmetic or dermatological agent, in particular for stimulating the beta-endorphin production in the skin. The invention enables to provide care for sensitive skins, in particular to fight against skin sensitivity, uncomfortable reactions, to provide sensations of well-being, and to produce a local analgesic action.

An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.

Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTI), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by particular liposomes or incorporated into a porous biocompatable matrix.

The invention relates to the use of cyclodextrin complexes containing lipoic acid, said complexes consisting of at least one representative of the series of unsubstituted .alpha.-cyclodextrin, .beta.-cyclodextrin and .gamma.-cyclodextrin, and at least one representative of the series of racemic .alpha.-lipoic acid, racemic dihydrolipoic acid and the derivatives thereof, for producing a food supplement, a functional food supplement, a clinical nutrition product and/or a cosmetic preparation in the non-medical field of application. Said complex, which contains at least 20 wt. % of the cyclodextrin component, preferably in food quality, can also contain water and reaction products or secondary reaction products from the complex production, especially .alpha.-cyclodextrin being used. The cyclodextrin/(dihydro)liponic acid complexes can be used, preferably combined with other bioactive components, aromas and/or texturing products, and also the standard formulation auxiliary agents, to produce an agent for preventing and/or treating symptoms of an inflammatory nature and especially arthritis, damage to the liver function and especially alcohol intoxication, paraesthesiae and neuropathies, and for producing agents having cytoprotective and/or antiphlogistic and/or antinociceptive (analgesic) properties and/or properties that counteract the formation of radicals. Said complexes can also preferably be used to produce an agent for stimulating glucose metabolism and/or transport in muscles and/or lipocytes, agents for reinforcing the energy metabolism of the body and the brain, agents for increasing the endurance, capacity, attentiveness, concentration of the memory, agents for the prevention and/or treatment of diabetes Typ2, and agents for caring for at least partially keratinised parts of the body, especially the skin, hair, fingernails and toenails. The invention enables products to be obtained, which can be taken by the end consumer under improved compliance conditions in the non-medical field of indication, due to the distinctive stability of the agents.

The present invention is directed to a lipolysis stimulator and a slimming agent which stimulate or facilitate lipolysis of accumulated adipose tissue, to thereby exert the body slimming effect. The lipolysis stimulator or the slimming agent of the present invention contains as an active ingredient any form of a plant or an extract thereof, the plant being selected from among common juniper, togenashi, rosehip, areca, polygala root, plantago herb, calumba, zuikorodoku, garden nasturtium, kidachiumanosuzukusa, bayberry, cogon grass, kohon, shoyokanzo, Japanese white birch, tanjin, kikubafuro, white mustard, common sunflower, ground ivy, Chinese wolfberry, Japanese pagota tree, sennenken, common fig, kankatto, Chinese hibiscus, usubaakaza, fenugreek, English walnut, sozuku, koniwa-zakura, gardenia, shima-kan-giku, akamino-akane, futaba-mugura, karoou, schizonepeta spike, purslane, karabyakushi, and prostrate knotweed.

Disclosed herein is a cosmetic method for remodelling the face and/or limiting age-related hollowing of the face, by applying to the skin of the face and/or the neck, a composition containing, in a physiologically acceptable medium, at least one extract of a non-fruiting non-photosynthetic filamentous bacterium.

Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of a terpene alcohol and a safe and effective amount of a retinoid; a safe and effective amount of a terpene alcohol and a safe and effective amount of a peptide; a safe and effective amount of a retinoid and a safe and effective amount of a peptide; a safe and effective amount of tocopherol sorbate; or a safe and effective amount of a vitamin B.sub.3 compound.

3-Sulfanylpropanamide compounds of formula (I) or salts and/or solvates thereof: are useful for caring for and/or making up keratin fibers, especially human keratin fibers, to induce and/or stimulate the growth, to stop the loss and/or to increase the density thereof, and/or to improve the appearance and/or to reduce the canities thereof, and/or to stimulate the pigmentation and/or to limit the depigmentation and/or bleaching thereof.

This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that said composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. This invention also relates to ophthalmic oil-in-water emulsions containing such compositions, said ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. This invention also relates to ophthalmic oil-in-water emulsions containing such compositions, said ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of acting on the nasal mucosa and/or being resorbed by it or which contains at least one volatile substance that acts on the deeper respiratory tract and/or is being resorbed by the deeper respiratory tract. Furthermore, the use of a medical skin care or cosmetical stick or of a stick material or of a refill cartridge containing said material for the topical or transmucosal application is described.

The electrotransfer of a nucleic acid into tissue cells, in particular in a muscle or a tumoral tissue, is carried out by an electric stimulation of the tissue as follows: first with at least one, preferably a single, pulse of a High Voltage field strength of between 200 and 2000 volts/cm second with a single pulse of Low Voltage field strength of between 50 and 200 volts/cm and of duration of between 300 ms and 2000 ms.

A method of treatment or prophylaxis of a cutaneous lesion in an animal the method comprising topically applying to an area of skin of the animal a composition comprising: one or more metal chelators; one or more transforming growth factor modulators; and one or more dermal penetration enhancers.

The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2',3'-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds, in particular as analgesic or anti-inflammatory compounds, or as disease modifying antirheumatic drugs (DMARDs), and to methods of preventing, treating or ameliorating pain or inflammation using these compounds.

The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R.sup.1, R.sup.2, R.sup.3 and R.sup.1 each a hydrogen atom or a substituent; R.sup.5 is a substituent; X.sup.- is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

In one aspect, an apparatus for promoting hemostasis includes oxidized cellulose in the form of a compressible, shapeable mass that is formed into a sheet for placement on a bleed site. In a second aspect, a sleeve for promoting hemostasis includes a tubular shell having at least one open end and oxidized cellulose material attached to an inner surface of the tubular shell. The open end of the tubular shell is dimensioned to receive a limb such that donning the sleeve causes at least a portion of the oxidized cellulose material to be placed in contact with a bleeding wound. In a third aspect, a bandage includes a substrate and oxidized cellulose material attached to a surface of the substrate. The oxidized cellulose material is arranged to contact a bleeding wound when the bandage is applied thereto.

The present invention relates to a sheet structure for application to a region of the human body, including the face, the structure comprising: a colored matrix; a first substrate situated on a first side of the matrix, a first surface of the sheet structure being defined by the first substrate; and a second substrate situated on a second side of the matrix, opposite the first, a second surface of the sheet structure being defined by the second substrate; the first and second substrates having different opacities, and at least one of the first and second substrates having an opacity that is low enough to enable the subjacent colored matrix to show through in such a manner that the first and second surfaces of the matrix appear to be of different colors.

Method for regulating the condition of mammalian skin comprising the steps of applying a first personal care composition to an area of skin where regulation is desired, wherein the first personal care composition comprises at least one skin care active selected from the group consisting of niacinamide, salicylic acid, peptides, N-acetyl glucosamine, panthenol, butylated hydroxytoluene, N-acyl amino acid compounds, hexamidine, green tea, ascorbyl glucoside, hexanediol, pentanediol, a skin lightening agent, a heat shock protein potentiator, and mixtures thereof, and delivering energy to the area of skin by contacting the skin with an energy delivery device for a treatment period of at least 21/2 minutes, wherein the energy delivery device comprises a skin-contacting surface that is controllably heatable to a temperature of from 37.degree. C. to 50.degree. C.

A personal care composition comprising a hydrophilic liquid, a structurant for said hydrophilic liquid, a surface active, a lipid, and an aqueous phase; wherein said lipid, said hydrophilic liquid, said structurant, and said surface active form a lipid phase; wherein said hydrophilic liquid, said structurant, and said surface active are connected to said lipid in said lipid phase. These compositions provide improved skin and/or hair moisturization, appearance, aesthetics and skin and/or hair conditioning during and/or after application, and are useful in providing improved deposition to the desired area of the skin and/or hair. The present invention is further directed to a method of using the personal care composition.

The invention relates to uses of an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent as a flame retardant or flame resistant foam. The hydrophobic solvent is preferably mineral oil; medium chain triglycerides; isopropyl myristearate or octyl dodecanol, silicone oil or vegetable oil or mixtures thereof. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, also making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil-soluble pharmaceutical and cosmetic agents.

The invention relates to a pharmaceutical composition based on an active ingredient that is enclosed in liposomes for topical, transdermal application. The interior of said liposomes comprises an acidic, aqueous medium containing at least one cholinesterase inhibitor, preferably from the group containing donepezil, rivastigmine, galantamine, physostigmine, heptylphysostigmine, phenserine, tolserine, cymserine, thiatolserine, thiacymserine, neostigmine, huperzine, tacrine, metrifonate and dichlorvos, or an enantiomer or derivative of at least one of said compounds. In addition, the invention relates to a method for producing said composition, optionally in a sterile form and also to the use of the liposomes charged with the active ingredient in various galenic formulations for topical, transdermal application with a depot effect in the epidermis, for the prophylaxis and/or treatment of cutaneous neuropathic pain or the loss of cutaneous sensory function as a result of neuropathy.

Compositions for controlling mammalian weight, said compositions comprising one or more lipolytic agents for stimulating mammalian lipolysis and/or thermogenic agents for modulating mammalian thermogenesis. Products, consumer and otherwise, comprising said compositions and methods of using both the present compositions and products to control mammalian weight.

The present invention relates to plant extracts and compositions containing such plant extracts useful in the treatment of viral disorders, including but not limited to the treatment of viral lesions resulting from viruses such as Herpes Simplex virus.

The invention relates to a cosmetic composition, characterized in that it contains, as active agent, an extract of Limnocitrus littoralis obtained by extraction with an extraction solvent selected from the group comprising alcohols and aqueous-alcoholic mixtures, in a cosmetically acceptable vehicle compatible with topical application. It further relates to a method of cosmetic treatment intended especially for soothing non-pathological skin manifestations of inflammatory origin and/or preventing and/or combating the effects of intrinsic and/or photoinduced ageing, comprising the application to the skin of a cosmetic composition of the invention.

The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that involve inhibiting the synthesis and/or release of renin from mast cells and/or inhibiting the activity of renin after release from mast cells. The methods of the invention can also involve inhibiting elements of the local renin-angiotensin system (e.g. inhibiting ACE and angiotensin II receptors), thereby inhibiting angiotensin II produced locally from mast-cell-derived renin.

The present invention relates to a knockout non-human animal whose genome comprises a disruption in at least one allele of the PHF3 gene, useful in developing drugs for diseases with the onset of atopic dermatitis or the like; a totipotent cell such as an ES cell which is essential to production of the above non-human animal; use thereof; and so on.

Substituted pyrazolopyrimidine derivatives of formula (I) wherein R.sup.1 represents chloro or bromo; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently represent e.g. hydrogen or C.sub.1-6-alkyl; R.sup.8 represents a radical R.sup.9 or a radical R.sup.10, whereby one of the two radicals R.sup.8 represents R.sup.9 and the other radical R.sup.8 represents Ret; R.sup.9 represents e.g. a phenyl or thiophene group, and R.sup.10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

The present invention relates to the use of silymarin, or of the main constituents thereof alone or as a mixture, chosen from silybin (or 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trih- ydroxy-4-oxobenzopyran-2-yl)benzodioxine), isosilybin, silydianin, silychristin, silandrin, silymonin and taxifolin, isolated enantiomers thereof and also salts thereof, for the manufacture of compositions for inducing, restoring or stimulating pigmentation of the skin, body hair or head hair. The invention also relates to the use of these agents for the manufacture of compositions for preserving the integrity of the hair, for limiting its loss and for stimulating hair regrowth. Silymarin or the constituents thereof alone or as a mixture are obtained by extraction of a plant of the genus Silybum.

The subject invention concerns materials and methods for treating or preventing any condition or disease that is treatable by a green tea polyphenol, or an analog, isomer, metabolite, or prodrug thereof, wherein the polyphenol is administered as an intranasal formulation to a person or animal in need of treatment. In one embodiment, the intranasal polyphenol formulation comprises (-)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. The subject invention also concerns materials and methods for treating or preventing dementia, such as AIDS-dementia in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof. In one embodiment, a composition of the invention increases expression or activity of a protein that exhibits .alpha.-secretase activity.

A personal care composition comprising a hydrophilic benefit active, a multi-wetting material, and an aqueous phase, wherein the hydrophilic benefit active may be a hydrophilic solid or a hydrophilic liquid with a structurant, wherein the multi-wetting material and the hydrophilic benefit active form a multi-wetting phase. These compositions provide improved skin and/or hair moisturization, appearance, aesthetics and skin and/or hair conditioning during and/or after application, and are useful in providing improved deposition to the desired area of the skin and/or hair. The present invention is further directed to a method of using the personal care composition.

The invention relates to the use of a modulator of at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor for the preparation of a pharmaceutical composition for treating rosacea.

Devices, bandages, kits and methods are described that can control or regulate the mechanical environment of a wound to ameliorate scar and/or keloid formation. The mechanical environment of a wound includes stress, strain, and any combination of stress and strain. The control of a wound's mechanical environment can be active, passive, dynamic, or static. The devices are configured to be removably secured to a skin surface in proximity to the wound site and shield the wound from endogenous and/or exogenous stress.

Compositions and therapeutic methods are provided that are useful agent for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGE The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Personal care composition comprising from about 0.1% to about 15% of an emulsifying silicone elastomer; from about 0.1% to about 40% of at least one solidifying agent; from about 1% to about 75% of an aqueous phase; from about 0.1% to about 74% water; wherein the composition is in the form of a water-in-oil emulsion, has a first hardness of from about 2 g to about 45 g at a first temperature of 21.degree. C., and a second hardness at a second temperature of 33.degree. C., wherein the second hardness is 65% or less of the first hardness.

The present invention relates to the use of a microorganism and/or a metabolite thereof to at least increase the amount of a COX-1 mRNA in a cell. The present invention further relates to the use of a microorganism and/or a metabolite thereof in the manufacture of a medicament to treat the side effects associated with nonsteroidal antiinflammatory drugs (NSAIDs). The present invention further relates to a pharmaceutical preparation comprising in combination a nonsteroidal antiinflammatory drug (NSAIDs) and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The present invention yet further relates to a pharmaceutical preparation comprising in combination betaine or a pharmaceutically acceptable salt thereof and a microorganism and/or a metabolite thereof which is capable of at least increasing the amount of a COX-1 mRNA in a cell. The microorganism may suitably be a bacterium, preferably from the genus Bifidobacterium.

The invention is based upon the discovery that the mitogen-activated protein kinase (MAPK) pathway can increase CA9 expression independently of HIF-1, as well as increasing CA9 expression under HIF-1-dependent pathways initiated by hypoxia or high cell density. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using MAPK pathway inhibitors. Preferably, the MAPK pathway inhibitors are raf kinase inhibitors, particularly the raf kinase inhibitor Sorafenib. Further disclosed are methods for patient therapy selection for MAPK pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises alicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatments of acne.

The present invention relates to a skin patch comprising a matrix adhering to the skin and containing at least one active cosmetic substance and a combination with a skin wrapping to generate an effective compression for the treatment of cellulite and/or striae.

Personal care composition comprising from about 0.1% to about 15% of an emulsifying silicone elastomer; from about 1% to about 90% of an aqueous phase; and from about 0.001% to about 5% of a coated particulate comprising a core material and a coating material, wherein the coated particulate has a size of from about 5 microns to about 100 microns and comprises from about 1% to about 15%, by weight of the coated particulate, of the coating material, and wherein the coating material comprises polysiloxanes.

The present invention relates to the use of a vitamin D compound active in up-regulating the expression and production of hCAP18 in humans for the manufacture of a medicament for treatment of conditions deficient in or benefiting from LL-37. The vitamin D active compound can be used as a medicament for treatment of injured tissues, chronic ulcers, burn wounds, skin infections and atopic dermatitis and for improving the microvasculature. UVB irradiation can also be used to up-regulate hCAP18.

The invention relates to a method of obtaining a firming active principle resulting from the solubilisation of Cucurbita pepo seed meal treated by means of enzymatic hydrolysis. The invention also relates to the active principle thus obtained and to the uses thereof in cosmetics.

The present invention relates to methods of influencing the flux or surface retention time of a topically active pharmaceutical ingredient through skin and formulations relating thereto.

Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 represent N or C--, whereby at least two of the groups Y.sup.1 to Y.sup.4 represent a carbon atom, R.sup.1 represents chloro or bromo, R.sup.2 to R.sup.7 represent e.g. hydrogen, methyl or ethyl; and R.sup.10 and R.sup.11 independently represent e.g. hydrogen or C.sub.1-C.sub.6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y.sup.1, Y.sup.2 and Y.sup.3 independently are e.g. CR.sup.10, NH, S or O, whereby at least one of Y.sup.1, Y.sup.2 and Y.sup.3 represents CR.sup.10; R.sup.1 represents chloro or bromo; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 represent e.g. hydrogen or C.sub.1-C.sub.6-alkyl, and R.sup.10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.

Sunscreen compositions having increased SPF contain at least one aqueous phase, at least one organic UV screening agent and/or at least one inorganic UV screening agent, notably at least one wetting agent, and an effective SPF-increasing amount of concave or annular particles of a silicone material, formulated into a physiologically acceptable medium therefor.

The invention relates to a cleansing composition suitable for topical application to human skin, more particularly to an oil-based cleansing composition containing a silicone elastomer gelling agent for removal of make-up from the skin.

Compositions of human proteins, methods and regimens for reducing the occurrence and growth of skin cancer, including melanoma, are provided. The methods include steps of administering topically on the skin tumor or a skin cancer-free area of compositions containing therapeutically effective amounts of human alkaline phosphatase, transferrin and .alpha.1-antitrypsin. In some embodiments, the composition is topically administered and includes all three proteins. Alkaline phosphatase, alone or in combination with transferrin and .alpha.1-antitrypsin can also be administered by injection with or without simultaneous or sequential topical administration. Administration of compositions topically and/or by injection can be part of a more complex cancer therapy including chemotherapy, radiotherapy, surgery, and electrochemotherapy.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

The present invention relates to a topical skin care composition having improved aesthetics containing a pentapeptide, a tacky solvent, and a dermatologically acceptable delivery system containing the tacky solvent in combination with a silicone elastomer and a carrier for the elastomer. The present invention also relates to methods of using such compositions to regulate the condition of mammalian skin while retaining good aesthetics.

The present invention relates to a composition comprising an aqueous or hydroalcoholic extract of bauhinia and to the use of an aqueous or hydroalcoholic extract of bauhinia for the preparation of a composition for the care, preservation or improvement of the general state of the skin or hair, for the prophylaxis or prevention of human skin or human hair ageing processes and for the prophylaxis and/or treatment of diseases associated with skin ageing.

The present invention relates to an inhibitor for the biosynthesis of gelatinase comprising ginsenoside F1 (20-O-.beta.-D-glucopyranosyl-20(S)-protopanaxatriol) or compound K (20-0-.beta.-D-glucopyranosyl-20(S)-protopanaxadiol), which is a chief metabolite of ginseng saponin, as an active ingredient; and a cosmetic/medical composition for the prevention of skin-aging comprising the same which is superior in inhibiting the decomposition of epidermal-dermal junction and also in accelerating the generation thereof.

Skin care compositions and methods for regulating the condition of mammalian keratinous tissue containing an effective amount of a dipalmitoyl hydroxyproline salt and a second skin care compound selected from hexamidine compounds, sugar amine compounds and their combination.

The present invention refers to a pharmaceutical formulation characterized in that it includes mainly clobetasolpropionate, minoxidil and 11 alpha hydroxyprogesterone as main active principles, besides other excipients, vitamins and/or minerals, and to its use in the treatment of skin diseases, mainly in the symptomatic treatment of psoriasis.

The invention concerns the use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation selected among the group consisting of alpha-eleostearic acid, catalpic acid, calendic acid, jacaric acid, licanic acid and beta-eleostearic acid for making a medicine for treating inflamatory diseases and/or metabolic disorders following an inflammation. The inflammatory diseases and/or metabolic disorders following an inflammation may be skin cancers, sun burn, benign summer light eruption, allergic and/or irritative reactions, gingivitis and periodontitis, vulvitis and vaginitis or arthritis and arthrosis. The medicine also enables healing to be promoted. Said fatty acid conjugates can also be used in the cosmetic treatment of cellulitis.

Described is a device and method for administration of molecules to tissue in vivo for various medical applications, the device comprising a single-needle electrode which provides for the ability, when the needle is inserted into tissue, such as skin or muscle, to pulse tissue with a non-uniform electric field sufficient to cause reversible poration of cells lying along or in close proximity to the track made by the needle upon its insertion into said tissue

The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Disclosed herein is a composition for topical application to skin, comprising, in a physiologically acceptable medium (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor. Further disclosed is the use of this combination in a composition suitable for topical application to the skin, as an agent for preventing or treating wrinkles and fine lines, such as expression wrinkles, as well as a cosmetic treatment process comprising applying to the skin the composition.

Methods for the prevention and treatment of skin damage arising from the exposure to UV radiation, air pollution and other stressors capable of leading to the formation of free radicals, using the small-dithiol protein glutaredoxin in a dermatologically acceptable carrier that can be applied topically are disclosed. Some embodiments may include other proteins such as superoxide dismutase and/or catalase, as well as other antioxidant molecules such as reduced glutathione, vitamin E, vitamin C, lycopene, astaxanthin and/or tocotrienols.

The invention relates to compositions comprising at least one peptide with a structure or structural pattern of .beta.-defensin 2 and/or its derivatives, especially human .beta.-defensin 2. The compositions are selected in particular from cosmetic and/or pharmaceutical compositions, cleaning and/or washing agents, water-treatment agents and cooling lubricants. The invention also relates to the use of peptides with a structure or structural pattern of .beta.-defensin 2 and/or its derivatives, especially human .beta.-defensin 2, as an antimicrobial active ingredient in the aforementioned agents.

A clear, water based, homogeneous insect repellent sunscreen composition, comprising an oil soluble hydrophobic sunscreen component, an amido insect repellent component, an alcohol component, and water.

A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthaleno- l free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.

Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable excipients; and process for preparing such compositions are provided. Also provided is a method for the management/treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders which comprises administering a pharmaceutically effective amount of such pharmaceutical composition to a subject in need of such treatment. The compositions of the present invention are non-greasy and easily water washable, and provides an enhanced localization of hydrophobic and/or amphiphilic active ingredients on the skin.

This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.

The present invention relates to new pharmaceutical combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein the groups R.sup.1, R.sup.2 and R.sup.3 may have the meanings given in the claims and specification, at least one further active substance 2, processes for preparing them and their use as medicaments.

The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.

The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions which can be treated by inhibiting tubulin polymerization and/or by inhibiting microtubuli-based motor proteins, in particular various tumor disorders.

Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches, orthopedic pins (including bone filling augmentation material), adhesion barriers, stents, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, atrial septal defect repair devices, pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, wound dressings, and hemostats. The polyhydroxyalkanoates can contain additives, be formed of mixtures of monomers or include pendant groups or modifications in their backbones, or can be chemically modified, all to alter the degradation rates. The polyhydroxyalkanoate compositions also provide favorable mechanical properties, biocompatibility, and degradation times within desirable time frames under physiological conditions.

An applicator for a device for electrokinetic delivery of medicament to a treatment site includes an applicator head having an active electrode, a matrix, and a medicament or a medicament and an electrically conductive carrier, carried by the matrix in electrical contact with the electrode. The cartridge includes a plurality of raised projections allowing the matrix and head to be ultrasonically welded one to the other. The electrode opens through a face of the head remote from the matrix for connection with an electrical connector carried by the device. A lid overlies the matrix and is releasably attached to a margin of the head. The lid includes layers of different materials with one of the layers formed of a metallic material having a discontinued interface with the lid and a tab carried by the lid.

High-aspect-ratio microdevices comprising microneedles, microknives and microblades and their manufacturing methods are disclosed. These devices can be used for the delivery of therapeutic agents across the skin or other tissue barriers to allow chemical and biological molecules getting into the circulation systems. The microneedles can also be used to withdraw body fluids for analysis of clinically relevant species when the device has an integrated body fluid sensor or sensor array in the vicinity of microneedles.

A physiologically acceptable composition, in particular a cosmetic composition, comprising at least one liquid fatty phase which comprises (i) at least one structuring polymer having a polymer skeleton which comprises at least one hydrocarbon-based repeating unit comprising at least one hetero atom; and (ii) at least one organogelator.

A film product composition that has a refractive index that matches the refractive index of the skin. The composition is made from polymers, polymers plus additives, including plasticizers, which have an average effective or actual refractive index of from 1.4 to 1.6. The refractive index of the composition matches the skin's refractive index, and therefore is helpful at masking skin fissures and imperfections such as wrinkles, cracks, abrasions and the like.

The present invention provides a moisturizing, cosmetic, or anti-wrinkle product comprising at least two hyaluronic acid fractions, or salts thereof, wherein a fraction has an average molecular weight in the range of 8,000-100,000 Da, and a fraction has an average molecular weight in the range of 500,000-1,100,000 Da.

Topically applicable colored and perfumed compositions, well suited for perfuming such human keratinous substrates as the skin, lips and/or integuments, contain, formulated into a cosmetically acceptable medium: a) at least 1% by weight of a perfuming substance; b) at least one volatile alcohol and/or volatile silicone oil; c) at least one coloring agent which is soluble in said medium; d) at least 0.2% by weight of at least one alkyl .beta.,.beta.'-diphenylacrylate or alkyl .alpha.-cyano-.beta.,.beta.'-diphenylacrylate compound; and a) at least one organic UV-A filter which is soluble in said medium; b) and, optionally, water.

The invention relates to substituted 1,3-diphenylprop-2-en-1-one derivative compounds, pharmaceutical and/or cosmetic compositions containing same, and the applications thereof in therapeutics and cosmetics. The invention also relates to a method for preparing said derivatives.

The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.

The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof by administering to the mammal a composition containing eggshell membranes processed eggshell membrane, eggshell membrane isolates and combinations thereof, alone or in combination with other active ingredients.

The invention relates to compositions and methods for making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically acceptable active agent carrier and a rosin ester which provides a crystal inhibiting and drug stabilizing effect on the active agents incorporated therein.

Disclosed herein is a composition with moxibustion effects comprising 20-40% by weight of an artemisia extract, 0-20% by weight of an auxiliary herbal material, 0-20% by weight of a resin and 30-60% by weight of a far-infrared radiating powder. Further disclosed is a method for preparing the composition, a press pellet for skin stimulation using the composition, and patch and sheet formulations comprising the composition. When the press pellet using the composition is attached to the affected parts or acupoints in a simple manner, acupuncture, moxibustion, far-infrared radiation and anion emission effects can be simultaneously attained.

The invention relates to methods for testing substances using multicellular in vitro test systems, in particular systems that resemble organs, and to devices and kits for carrying out said methods.

The invention relates to a novel peptide, a pharmaceutical composition containing said peptide and to the use of said composition for treating various skin alternations. More particularly, the treatment of said alterations consists in reinforcing the derma-epidermal junction and the cell-matrix and/or cell-cell adherence of epidermis and in promoting the repair of a cutaneous surface.

The invention provides (1,3)di-acylated vitamin D.sub.3 analogs of cholecalciferol, substituted at carbon (20) with methyl or cyclopropyl wherein carbon (16) is a single or double bond, and carbon (23) is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated at carbon (25). The invention provides pharmaceutically acceptable esters, salts, and pro-drugs thereof. Methods for using the compounds to treat vitamin D.sub.3 associated states, and pharmaceutical compositions containing the compounds are also disclosed.

The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

The invention relates to novel pyrrolodihydroisoquinoline derivatives which are efficacious inhibitors of cellular (hyper)proliferation and/or inducers of apoptosis in cancer cells.

The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.

Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months.

Vitamin and flavonoid containing compositions are provided that are stable to degradation. Stabilized compositions include one or more features including a hygroscopic solvent at a sufficient concentration to provide an Aw value of the hygroscopic vitamin and or flavonoid containing composition of less than 0.9, antioxidant flavonoids that are preferentially oxidized before the vitamin, preservatives, and hydrocarbon propellants selected to reduce the oxidation potential of the composition.

Personal care compositions containing an active selected from the group consisting of Lauryl p-Cresol Ketoxime, Bis-abolol and ginger extract, 4-(1-Phenylethyl)1,3-benzenediol, Lupin (Lupinus albus) oil & wheat (Triticum vulgare) germ oil unsaponifiables, Hydrolyzed lupin protein, Extract of L-lysine and L-arginine peptides, Oil soluble vitamin C, Evodia rutaecarpa fruit extract, Zinc pidolate and zinc PCA, Unsaponifiable fraction of olive (olea Europaea) oil, Alpha-linoleic acid, p-thymol, and combinations thereof are provided. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

An acidic composition for external use which contains an acidic poly saccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture, and shows a stronger cosmetic or therapeutic effects than conventional compositions.

The present invention relates to an EC SOD, a cell-transducing EC SOLD, and the use thereof. More particularly, the present invention relates to an EC SOD, an EC SOD fusion protein enhanced Cell-transduction ability, and the use thereof for preventing or treating skin diseases.

The present invention provides a herpes virus in which a non-essential gene for replication is inactivated. More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3 or UL56. The herpes virus may be preferably a herpes simplex virus, and more preferably herpes simplex virus 1 or herpes simplex virus 2. The present invention provides a method, composition and use for treating various diseases or disorders including tumor and infectious diseases. The present invention also provides a method, composition and use for activating a prodrug.

A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics select from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted with a liquid are disclosed. Methods of making and using solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted with a liquid are also disclosed.

The use of Myrica gale oil in the manufacture of a composition for the treatment of the skin or other exposed surfaces of the body is disclosed. Compositons prepared in accordance with the invention are particularly useful as anti-acne and anti-dandruff products. Myrica gale oil may bai used with other active agents which have complementary benefits.

Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of the matrix degrading enzymes and (ii) a cytokine inhibitor that alleviates inflammation and thus also alleviate neutrophil infiltration. Alleviating the matrix degradation and renormalizing procollagen biosynthesis allows for reduced inflammation and better natural repair of acne-affected skin. Inhibiting cytokines alleviates induction of MMPs in resident skin cells, and also alleviates inflammation with its concommitant induction of neutrophils from the blood stream bringing MMPs and elastase into the acne lesion. Diminishing the presence of matrix-degrading enzymes in the acne lesion reduces imperfect repair of the skin and thus decreases scarring in acne-affected skin.

The invention relates to novel keratin-binding protein active substances, and also to the production and use thereof. Particularly suitable keratin-binding polypeptides are sequences which are contained in human desmoplakin or are derived therefrom by altering the human desmoplakin polypeptide sequences such as amino acid insertions, substitutions or deletions. The polypeptide sequences of the human desmoplakin is represented in SEQ ID NO: 1. A suitable keratin-binding domain (domain B) is the polypeptide sequence SEQ ID NO: 1, position 2193 2481, in addition to functional equivalents thereof. An additional keratin-binding domain (domain C) is the polypeptide sequence SEQ ID NO: 1, position 2606 2871 and the functional equivalents thereof.

The present invention relates to aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationogenic groups which comprises at least one monomer with at least one protonatable nitrogen atom and at least one further monomer copolymerizable therewith in copolymerized form, and at least one cosmetically acceptable carrier, where the pH of the aqueous preparation has a value in the range from pH 4 to pH 6.

An object of the invention is to provide a composition for transmucosal administration that enables pharmacologically active peptides and proteins to be efficiently absorbed through the mucosa such as the pulmonary mucosa, nasal mucosa, oral mucosa, vaginal mucosa, gastric mucosa, gastrointestinal mucosa or the like. A composition for transmucosal administration are prepared by adding (i) at least one member selected from the group consisting of peptides and proteins having pharmacological activity; and (ii) at least one member selected from the group consisting of chitosan oligosaccharides having a polymerization degree of from 2 to 20, derivatives thereof, glucosamine, and salts thereof.

Methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of undamaged mammalian skin are disclosed. The methods comprise the step of administering to an area of the skin a composition comprising a therapeutically effective amount of human placental alkaline phosphatase, or an active derivative. The composition can be administered topically or by injection. Embodiments of the invention also provide regimens for restoring or maintaining the strength and thickness of aging skin, comprising periodically administering a composition by topical application. Other embodiments of the invention further provide methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of transplanted skin. A composition for topical application is also provided by some embodiments of the invention.

A personal care composition may comprise a member selected from a group consisting of kinetin, zeatin, and combinations thereof; niacinamide; and a dermatologically-acceptable carrier. A personal care composition may comprise an N-acyl amino acid compound, a skin care active, a member selected from a group consisting of kinetin, zeatin, and combinations thereof, and a dermatologically-acceptable carrier. A personal care composition may comprise a hexamidine compound, a skin care active, a member selected from a group consisting of kinetin, zeatin, and combinations thereof, and a dermatologically acceptable carrier.

The invention provides compounds, compositions, and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, for the preparation of a medicament intended to treat an inflammatory disorder wherein y is any integer from 1 to 8; z is any integer from 1 to 8; with the proviso that y and z cannot both equal 1; X is --C --(Y).sub.k--(R.sup.1).sub.n or SO.sub.2--(Y).sub.k (R.sup.1).sub.n; k is 0 or 1; Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or Y is a cycloalkenyl or polycycloalkenyl group.

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

A thienopyrimidine of formula (I): and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110.alpha. subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

A composition containing chlorhexidine enabling treatment of many types of discomforts, including hemorrhoid pain and itching without discomfort.

A brush for hygienic purposes includes a handle with a lower and an upper portion and a head. The upper portion is sized and shaped to capture the head. Preferably the head is a removable cartridge and includes a flexible base with a plurality bristles and a pad with holes disposed over the bristles. The pad could be a foam or sponge matrix or could be a stack of sheets removable one at a time. Upper portion of the handle is curved to provide a predetermined shape to the head. Optionally, a vibrating device is incorporated in the brush so that the brush can be used as to massage the skin or scalp.

Compositions for topical application to skin and/or hair, comprising photoprotecting synergistically effective amounts of sunscreen active agents octinoxate, octocrylene, and amiloxate; methods of protecting skin and/or hair against deleterious effects of sunlight/UV radiation by topical application of compositions.

Composition and methods for alleviating or eliminating wounds and/burns by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate active ingredient.

The present invention relates to a compound represented by Formula [I]: whereinX is O, S, NH or CH.sub.2; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4 and Y.sub.5, which may be identical or different, are each CH or N; however, at least one of Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4 and Y.sub.5 is N; Z.sub.1 and Z.sub.2, which may be identical or different, are each CH or N; n is an integer from 1 to 3; R.sub.1 is a C.sub.3-C.sub.8 cycloalkyl group, a C.sub.6-C.sub.10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R.sub.2 and R.sub.3, which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C.sub.3-C.sub.8 cycloalkyl group, a C.sub.6-C.sub.10 aryl group, an aromatic heterocyclic ring, or the like; and R.sub.4 is a hydrogen atom, a lower alkyl group, a C.sub.3-C.sub.6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.

Disclosed is a novel formulation and process for the effective repelling of insects without the adverse effects of repelling fish. Further the formulation is stable enough for long term storage, has a high rate of durability on the skin, and has been shown in cases to attract fish.

the present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

The invention relates to the use of a binding member which binds to Lewis.sup.y and Lewis.sup.b haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewis.sup.y and Lewis.sup.b haptens and cancer cells and induces cells death.

The present invention provides a pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases to be administered simultaneously or separately with an interval comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, as active ingredients; and the like.

The invention is an article of manufacture, comprising a blend of: (A) from 1 to 50 weight percent of at least one block copolymer, wherein the block copolymer has at least one polystyrene block and at least one unsaturated rubber segment; and (B) from 99 to 50 weight percent of a natural oil. The natural oil of this invention is of natural animal, plant or vegetable oils or mixtures thereof, and the block copolymers have a polystyrene block and a rubber block where the rubber blocks are unsaturated rubbers such as polyisoprene, polybutadiene, or mixtures thereof. The block copolymers useful for the present invention are triblock polymers, radial (star) polymers, multiblock polymers, diblock polymers, or mixtures thereof.

Compositions comprising a first sensate, a second sensate, and a cationic polymeric compound are described, as well as methods for using such compositions in oral care and personal care applications.

This invention is related to a freeze-dried product of cells of brown algae, the process for obtaining thereof, a cosmetic composition containing thereof, a food complement containing thereof, and the use thereof.

The present invention relates to amphoteric copolymers which comprise ethyl methacrylate, if appropriate a N-vinyllactam compound, at least one monoethylenically unsaturated carboxylic acid and at least one compound with .alpha.,.beta.-ethylenically unsaturated double bond and at least one cationogenic and/or cationic group in copolymerized form, to cosmetic and pharmaceutical compositions which comprise such copolymers, to preparation methods, and to the use of these copolymers.

The invention relates to substances which are capable of protecting FGF-2, to a composition for preventing or controlling degradation of FGF-2, and a method of protecting FGF-2 in the skin from degradation. In particular, the invention relates to an extract of Hibiscus Abelmoschus or ambrette, a rebokza extract, a gougizi berry extract, a banha extract, a lessonia extract, a mustard flour extract, a wooyin extract, a barley extract, and/or a sesame extract, in amounts effective to protect FGF-2 from its degradation. Further, the present invention allows the extracellular matrix to be restructured, particularly at the dermis, which is useful, for example, for controlling aging.

A capsule for cosmetic and/or dermatological ingredients and processes for the production thereof. The capsule comprises an envelope which is solid, semisolid and/or dimensionally stable and comprises one or more substances which are selected from waxes, emulsifiers, and natural and synthetic polymers. The capsule may also comprise a filling.

A method and apparatus for local infusion of a variety of biological response modifiers (BRMs) and chemotherapeutic agents including tumor necrosis factors (TNF) is described. In one embodiment, the device contains a synthetic pouch compartmentalized into three or more chambers, and an electronic apparatus controlling and modulating the delivery of the agents to the site of the tumor, so as to achieve a desired regimen in support of the elimination of a tumor burden. In one embodiment, an electronic system provides tailored and controlled regulation of the administration of such agents, using sensors to monitor the progress of the treatment. Desired dosing and scheduling of anti-tumor agents in a local setting is provided In one embodiment, active control and regulation of the administration of medicating agents is attached to a synthetic pouch and with the aid of a piezoelectric valve and pump actuating mechanism. The apparatus provides the desired dose, duration and timing of dose delivery. In one embodiment, reporting the events in the tumor site via an RF link to the external control box is provided.

Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects.

The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

Compositions comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compositions comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

The invention relates to compounds of formula (I) or a pharmaceutically acceptable solvate or salt thereof, including a solvate of such a salt, wherein R.sup.1 is a group such that a compound of formula (I) is a prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form or an active metabolite thereof. The compounds find particular use in the treatment or prophylaxis of urinary incontinence.

Personal care compositions containing at an alpha-glucan and/or beta-glucan; at least one additional skin and/or hair care active selected from the group consisting of sugar amine, vitamin B.sub.3, retinoids, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard seed extract, glycyrrhizic acid, glycyrrhetinic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), menthyl anthranilate, cetyl pyridinium chloride, ergothioneine, vanillin or its derivatives, diethylhexyl syrinylidene malonate, melanostatine, sterol esters, tetrahydrocurcumin, their derivatives, their precursors, and combinations thereof; and a dermatologically acceptable carrier.

This invention relates generally to the field of antimicrobial teat care compositions. More particularly, it relates to a skin-adhering antimicrobial composition comprising a copolymer which contains methacrylic acid and 2-acrylamido-2-methyl-propane sulfonic acid (AMPS) monomeric units, the antimicrobial composition hindering the transfer of bacteria from the environment to underlying teat surfaces and orifices, and which is compatible with both mammalian tissue, including skin, and teat dip compositions.

Compositions containing a protease inhibitor and methods of use and production are described. The compositions contain an effective amount of a protease inhibitor in a carrier or diluent and are used for the treatment of inflammatory or hyperproliferic mucocutaneous disorders. The carrier or diluent is preferably a gelling agent, and the composition is a topical gel formulation containing alpha 1-antitrypsin in an aqueous liquid or viscous gel formulation.

The present invention includes a clear cosmetic stick that has a clarity that is stable over a temperature of 5 to 45 degrees Centigrade for a time period of at least about twelve months. The clear cosmetic stick includes one or more of a branched chain fatty acid surfactant and a straight-chain fatty alcohol surfactant.

The present invention relates to nanoparticle systems for the release of biologically active molecules formed by the chitosan polymer or its derivatives, chemically modified with polyethylene glycol and crosslinked with a crosslinking agent. These systems are especially useful for pharmaceutical compositions, vaccines and cosmetic formulations.

A process reduces the microbial content in land mass by providing molecular iodine in the land mass in a concentration in aqueous material in the land mass of at least 5 or 10 parts per million. The molecular iodine may be added in gaseous or liquid or solid state, and may be formed in situ using available water, added water and/or alcohol in the reaction.

A composition of multilamellar vesicles for the delivery of pharmaceutically-active substances through the skin of a mammal, the composition including between about 1 to about 30% Cyclomethicone 5-.N.F., between about 1 to about 30% PEG-12 Dimethicone; between about 3 to about 14% Cyclopentasiloxane and PEG 12 Dimethicone Crosspolymers, between about 0.9 to about 9% Lauryl PEG/PPG-18/18 Methicone, between about 2 to 5% Sepigel 305, between about 1 to about 4%, Carbopol ETD 2020 solution (2%), up to 100% Water, and Sodium hydroxide to a pH between about 6-6.5.

The present invention relates to dry delivery system comprising a xerogel or film with applied active ingredients for topical active ingredient delivery or other purposes. Said delivery system are obtainable by a method according to the invention. The present invention also provides for methods for achieving defined localization of stable or unstable active substances on dry xerogels or films, which can be reconstituted into hydrogels. From the obtained delivery systems, the active substances are released with advantageous release kinetics.

Germicidal compositions with enhanced activity towards killing microbiological spores and vetgetative cells comprising certain quaternary ammonium compounds (QACs), phenolic compounds, monohydric alcohols, hydrogen peroxide, iodine, triclocarban, triclosan or combinations thereof with one or more spore coat opening agents. The invention also provides for the application of the germicidal compositions to animate and inanimate surfaces to help kill germs and protect against the risk of infection from bacteria, molds, yeasts, fungi, viruses, and microbiological spores.

The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form. The compositions are particularly useful in the regulation of skin conditions.

Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.

Method for effecting a controlled heating of tissue within the region of dermis which employs heater implants which are configured with a thermally insulative generally flat support functioning as a thermal barrier. From the surface of this thermal barrier are supported one or more electrodes within a radiofrequency excitable circuit as well as an associated temperature sensing circuit. A model of R.F. current path flow is developed resulting in a current path index permitting a prediction of current path flow. Improved electrode excitation is developed with an intermittent R.F. excitation of electrodes shortening therapy time and improving skin protection against thermal trauma.

Epidermis equivalents capable of pigmentation include cells derived from the differentiation of matrix cells; reconstructed skins comprised thereof, optionally containing hair follicles, are useful for evaluating the effect of topical cosmetic, pharmaceutical or dermatological products and may also be used for the preparation of grafts suited to be transplanted on mammals, more particularly on human patients such as victims of third-degree burns.

A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of smooth muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function:Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Disclosed is a wound healing composition comprising a mixture of substances that are obtained from diptera larvae, are heat-resistant at 100.degree. C., and have molecular weights ranging from 500 to 10,000 Dalton. Also, disclosed are the use of said composition as well as a method for the production thereof.

Flavored chewable foams for the oral care sector are produced from a polyurethane-polyurea and a sensorially active substance (e.g., taste substance and/or aroma substance) by foaming a polyurethane-urea dispersion, drying that dispersion and incorporating the sensorially active substance into the polyurethane-urea dispersion before, during or after foaming of the dispersion.

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

A motorized personal skin care implement capable of use with a disposable, single-use, skin care pad is disclosed with a molded hook arrangement for releasably but firmly holding the pad while cleansing or treating the skin but allowing for quick removal and replacement with a fresh cleansing or treatment pad. A method of using the skin care implement and a kit containing at least one pad and the implement is also described.

Dermal drops that, when applied topically to animal subjects, can ameliorate symptoms of conditions such as diabetes and Parkinson's disease are prepared as concentrates of the culture filtrate of a Basidiomycete fungus grown under appropriate conditions. The concentrate can also be used as a convenient source of liquid compost factor.

The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same as, or different from, the first constituent moiety. The first and second constituent moieties are so linked that they are easily transported into or across the dermis, into the skin, or into the blood or lymphatic system, and are reconstituted in vivo to form the first and second constituent moieties.

Disclosed is a pain relief composition comprising an effective amount of a nerve inhibiting component, including capsaicin, a capsaicinoid or a capsaicin analogue, which numbs or inhibits the nerve endings that signal pain, in combination with at least one of the following: an effective amount of an inflammation control component which is designed to reduce immediate pain and discourage future pain in the joints and muscles; an effective amount of a cooling component; an effective amount of a heat minimizing or blocking component; an effective amount of a circulation increasing component which effectuates better penetration of the actives to the skin and nerves; and an effective amount of a soothing and anti-inflammatory complex for the joints and/or muscles comprising Glucosamine sulfate or HCl, Zingiber officiniale (Ginger Root) extract, Methyl sulfonylmethane (MSM), Polygonum cuspidatum (Mexican Bamboo) extract, Aloe barbadensis leaf, and Salix alba (white willow) bark extract. Additionally, the composition includes an encapsulation or entrapment system for a timed release delivery.

There is provided a composition for promoting the production of and/or enhancing the activity of fibulin-5, said composition comprising as an active ingredient one or a plurality of pharmaceutical agents selected from the group consisting of extracts of Caesalpinia crista, extracts of Psophocarpus tetragonolobus, phytic acid and a pharmaceutically acceptable salt thereof, and L- hydroxyproline and a pharmaceutically acceptable salt thereof.

An antiperspirant system which includes a water-based antiperspirant which feels comfortable on the skin and a capillary aerosol dispenser is disclosed. The antiperspirant system includes: a pressurized container (51) in which a water-based antiperspirant composition with one or more astringent active salts and a propellant are present, a valved outlet (41) on the surface of the container through which antiperspirant is ejected into an inlet port (111) of a capillary tube (11), a capillary tube (11) with one inlet port (111) and one exit port through which antiperspirant is dispensed from the system, and a coupling means (12) to closely couple the inlet port of the capillary tube (11) to the valved outlet (41) of the pressurized container (51). The void volume between the inlet port and the valved outlet is minimized, such that upon use of the antiperspirant system, the valved outlet, the capillary tube, and the void volume do not become obstructed by solid deposits of the astringent active salt.

A product release system for atomizing cosmetic hair or skin compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition containing at least one UV filter. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be a gel, wax, or emulsion.

The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are methods of making and using the additives.

The present invention relates to polygalactomannan compositions, and more particularly guar gum compositions, which, when crosslinked with organic chelating agents, such as non-borate metal salt or chelates, to form discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as washing. The guar and its derivatives are desirable for use in applications such as personal care and household care products.

The present invention relates to polygalactomannan compositions, and more particularly cationic guar gum compositions, which, when crosslinked with glyoxal, from discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as washing. The guar and its derivatives are desirable for use in applications such as personal care, household care products and the like.

Methods for providing color to animate objects, i.e., living things, as well as compositions, such as personal care compositions and agrochemical compositions, suitable for application to such animate objects. The compositions include colorants that include a radiation diffraction material comprising an ordered periodic array of particles held in a matrix, and/or a dispersion of polymer-enclosed nanoparticles.

The invention provides a delivery system for a biologically active agent comprising a gemini surfactant in admixture with the biologically active agent in a topical formulation for treatment of skin disorders or metabolic diseases. The invention also provides pharmaceutical compositions in topical formulations comprising the delivery system as set out above, in admixture with pharmaceutically acceptable carriers, diluents, excipients, or supplements suitable for application to the skin or mucosal membrane. Methods of preparation and use are also described.

The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.

The present invention relates to a cosmetic composition which contains electric carriers apart from specific active agents and auxiliaries. According to the present invention, the composition contains 0.1 to 10% by weight of a cosmetically acceptable, solid electret material with a particle size of 0.05 to 100 .mu.m, which electret material is to be brought in the electrete state and has an induced permanent dipole moment and a permanent electric field with a field strength of 500 to 10.sup.7 Vm.sup.-1, as well as cosmetic carrier substances, auxiliaries, further active agents or a mixture thereof in an amount ranging up to 100% by weight.

Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.

This invention relates to a transdermal system containing fentanyl as the active ingredient and consisting of or comprising a substrate, a mixture of the following ingredients applied to the substrate: the active ingredient, an oil-based aloe vera extract, a resin, and an adhesive, as well as a layer laminated to the mixture applied to the substrate.

A transdermal therapeutic system (TTS) that is essentially composed of two compartments and is provided with activatable oversaturation and controlled permeation promotion. The invention more particularly relates to a TTS wherein an oversaturated active ingredient solution is produced in an active-substance-containing polymer matrix when the system is applied to the skin, caused by the controlled supply of one or several substances promoting the permeation of the pharmaceutical active ingredient; to the two compartments from which the inventive transdermal therapeutic system is assembled; and to the production of the transdermal therapeutic system from the two compartments.

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and X have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the use of an inflammatory disease using the lignan compound. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE.sub.2, COX-2 and TNF-.alpha.. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

The present invention relates to a system for intradermal or transdermal delivery of oligonucleotides or polynucleotides and to methods of use thereof. Particularly, the present invention relates to a system comprising an apparatus that generates micro-channels in the skin of a subject in conjunction with a pharmaceutical composition comprising an oligonucleotide or polynucleotide, wherein the oligonucleotide or polynucleotide can be delivered into the organism through the micro-channels. The system and methods of the present invention achieve expression of target proteins encoded by the polynucleotides, and hence are useful in immunization and gene therapy.

Enhanced SPF and/or reduced fluffing fluid compositions for photoprotecting the skin and/or the hair against the damaging effects of ultraviolet radiation, contain: (a) at least one photoprotective system capable of screening out UV radiation; and (b) at least one ester-terminated poly(ester amide) (ETPEA) polymer, formulated into (c) a topically applicable, cosmetically acceptable aqueous support therefor; the subject aqueous compositions are advantageously vaporizable, especially in the form of sprays, confined within a pressurization device.

A cosmetic composition for skin care containing retinol and piceatannol is disclosed. In embodiments of the cosmetic composition piceatannol is preferably present in an amount of 0.001 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the composition. The piceatannol-containing cosmetic composition of the present invention alleviates adverse effects of retinol, such as skin irritation, and also enhances the skin care effect of retinol.

Compositions, in particular, for the treatment of the hair or of the skin, comprising at least one compound which is selected from L-carnitine or L-carnitine derivatives and at least one further substance which is selected from the group formed from active ingredients obtainable from the plants of the genus Echinacea, and also taurine and derivatives thereof.

This invention relates to pharmaceutical water, which comprises from 99.760 to 99.999% of light isotopologue .sup.1H.sub.2 .sup.16O and up to 100% of residual isotopologues .sup.1H.sub.2 .sup.17O, .sup.1H.sub.2 .sup.18O, .sup.1H.sup.2H.sup.16O, .sup.1H.sup.2H.sup.17O, .sup.1H.sub.2H .sup.18O, .sup.2H.sub.2 .sup.16O, .sup.2H.sub.2 .sup.17O, and .sup.2H.sub.2 .sup.18O, for the production of finished product, intermediate reagent preparation, and analytical processes in pharmaceutical industry. Further, the invention relates to pharmaceutical compositions comprising a biologically active agent and said pharmaceutical water, wherein said agent is selected from the group consisting of drugs, physiologically active peptides, physiologically active proteins, and nucleic acids. Further, the invention relates to method of administering a biologically active agent to a mammal in need thereof, which method comprises a step of administering to said mammal said therapeutic composition.

A cosmetic composition is disclosed containing hydrophilic, spherical powder of polymethylsilsesquioxane having a particle size ranged from 1-20 microns with a narrow particle size distribution. The hydrophilic, spherical powder in the composition is prepared by a process comprising (1) hydrolyzing and condensing methyltrimethoxysilane in water in the presence of a thickener as suspending agent, an oil as surface tension modifier and an acid or base as catalyst to form spherical particles, (2) post-hydrolyzing the spherical particles in an aqueous NaOH solution and (3) purifying the spherical particles by repeated washing and vacuum stripping.

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

The invention relates to a medical device comprising non-sintered bioactive glass particles or fibres having a diameter in the range 5-100 .mu.m, bioactive glass comprising SiO.sub.2, Na.sub.2O, CaO, K.sub.2O, MgO, B.sub.2O.sub.3 and P.sub.2O.sub.5, wherein the amount of SiO.sub.2 is 50-65 wt-% of the final total weight, Na.sub.2O is 5-26 wt-% of the final total weight, CaO is 10-25 wt-% of the final total weight, K.sub.2O is 0-15 wt-% of the final total weight, MgO is 0-6 wt-% of the final total weight, B.sub.2O.sub.3 is 0-4 wt-% of the final total weight, and P.sub.2O.sub.5 is 0-4 wt-% of the final total weight, provided that the total amount of Na.sub.2O and K.sub.2O is 10-30 wt-% of the final total weight The device is essentially drug free. The invention also relates to the use of said composition for treating lesions associated with compromised or poor vascularisation and for preventing avascular fibrosis.

The invention relates to bactericidal formulations that come into contact with human body, particularly wash formulations including liquid soaps, comprising perfume ingredients active against gram-negative bacteria. Such compositions contact the target site, for example the skin surface, only for a short time, usually not longer than 30 seconds. Therefore the antibacterial action has to be of the bactericidal type and rapid. Furthermore, the bactericidal activity has to be sufficiently high to ensure an effect even when applied to wet substrates that will dilute the bactericidal formulation.

A method for forming an active material containing coating on a substrate, which method comprises the steps of: i) introducing one or more gaseous or atomised liquid and/or solid coating-forming materials which undergo chemical bond forming reactions within a plasma environment and one or more active materials which substantially do not undergo chemical bond forming reactions within a plasma environment, into an atmospheric or low pressure non-thermal equilibrium plasma discharge and/or an excited gas stream resulting therefrom, and ii) exposing the substrate to the resulting mixture of atomised coating-forming and at least one active material which are deposited onto the substrate surface to form a coating; wherein the substrate is not a wipe, cloth or sponge for household care or depilatory care or a water solute household cleaning unit dose product.

The present invention relates to compositions and methods for treating cancer and other disease states characterized by abnormal cell proliferation. In particular, the present invention relates to certain novel non-nucleoside pharmacologically active compounds that alter telomere and telomerase functions, regulate cell proliferation and/or treat cancer and other diseases characterized by abnormal cell proliferation. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, and to treat cancer or to inhibit the proliferation of the rumor cells, and to treat other proliferative conditions.

New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivates are also disclosed.

The present invention relates to a composition comprising, in a physiologically acceptable medium, at least one copolymer of a styrene monomer and of an ethylenically unsaturated dicarboxylic acid and at least one anti-seborrhoeic active agent.

The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis. In particular the invention relates to treatment of psoriasis, and preferably to treatment of psoriasis with valrubicin topically applied.

A drug for inhibiting the production of matrix metalloproteinase-9 which contains leptomycin B or its derivative as the active ingredient can specifically inhibit the production of MMP-9 compared with MMP-2, furthermore, has an effect of inhibiting the production of MMP-9 even under stimulating the differentiation by adding calcium at a high concentration or adding TGF-.beta., and under stimulating for inducing inflammation by adding TNF-.alpha. or adding IL-2.alpha..

Essentially alcohol-free deodorizing aerosol compositions which contain selected oils, a skin-cooling active substance, a deodorizing active substance and a propellant gas.

Disclosed is whitening cosmetic composition comprising extract of Pulsatillae Radix as main ingredient if necessary, additionally comprising ingredient(s) selected from the group consisting of ranunculin, deoxypodophyllotoxin and 3-O-.alpha.-L-ramnopyranosyl(1.fwdarw.2)-[.beta.-D-glucopyranosyl(1-4)]-.- alpha.-L-arabinopyranoside(SB365) obtained from the extract of Pulsatillae Radix and auxiliary ingredient(s) selected from the group consisting extract of Ulmaceae Cortex and extract of Glycyrrhizae Radix. The present composition has an excellent whitening effect.

According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats to prevent reinfestation of house dust mites, molds and cockroaches.

A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of viral infections and the diseases associated with such viral infections. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made compositions comprising a substance exhibiting Tubercin and/or SSM activity or a functional derivative thereof.

The present invention provides a method of inhibiting formation of solid hydrates in a conduit used to contain a flowing, water-containing hydrocarbon, which method comprises introducing into said hydrocarbon in said conduit a gas which raises the pressure threshold for hydrate formation for said water-containing hydrocarbon, said gas being introduced in a manner which causes it to travel along at least part of said conduit in the direction of hydrocarbon flow.

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

A method for manufacturing an inorganic honeycomb structure that resists water damage after drying comprises compounding a base batch mixture including inorganic powders, a batch cross-link agent, an aqueous vehicle, and a cross-linkable batch constituent, and forming the batch mixture into a honeycomb core or skin component while reacting the cross-link agent with cross-linkable batch constituent.

To provide an implant material which exhibits relatively high mechanical binding with an osteoblast and also high strength. [MEANS FOR SOLVING PROBLEMS] A scaffold material (10) capable of inducing a biological hard tissue, which comprises a rod (11) having a trunk portion (21) and bride girders (22), a binding layer (13) formed on the periphery of the rod and a metal fiber layer (14) formed on the periphery of the binding layer, and which further has a reinforcing layer (15) formed on the periphery of the metal fiber layer (14). The binding layer (13) has pores having an average pore size of less than 100 m, and the metal fiber layer (14) has pores having an average pore size of 100 to 400 m.

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention relates to prodrugs of sulopenem of formula (I): wherein R.sup.1 is --(C.sub.2-C.sub.8)alkyl, or a solvate or hydrate thereof. The invention also relates to the preparation, formulation, and use of the prodrugs of sulopenem to treat a disorder such as an infection in a patient in need thereof.

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5 and X have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.

Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical formulation vehicle, and methods of using these formulations to inhibit skin irritation, are disclosed.

The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.

The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.

The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. The present invention further provides methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using such foamable compositions; and to methods of producing such foams having an improved bubble size.

The present application relates to a cosmetic composition comprising at least one ester corresponding to formula (I) below: R1COOR2 (I) in which R1 represents H or a linear or branched hydrocarbon-based radical, and R2 represents a linear or branched hydrocarbon-based radical, with the proviso that: when R2 is a linear hydrocarbon-based radical and R1 is H or a linear hydrocarbon-based radical, then 7.ltoreq.R1+R2.ltoreq.8; and when at least one of R1 and R2 is a branched hydrocarbon-based radical, then 8.ltoreq.R1+R2.ltoreq.10, with the proviso that, when R1 is tert-butyl, then R2 is not isohexyl. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

UV-photoprotective, topically applicable cosmetic/dermatological compositions contain: (a) at least one silicon-containing s-triazine substituted with two aminobenzoate or aminobenzamide groups of specific formula (I),and (b) at least one non-silicon-containing lipophilic 1,3,5-triazine compound UV-screening agent, such compositions having improved photoprotective effectiveness in the UV-B range and the 1,3,5-triazine compound(s) being improvedly soluble therein.

The present invention relates to prevention of congenital deformations The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events gene expression during prenatal development, post-natal development and during development in the adult organism.

The invention provides a cross-linkable composition comprising a saccharide-siloxane copolymer according to a specified structural formula, a crosslinking agent, and, optionally, solvent. Cross-linked polymeric networks, cured coatings, and articles of manufacture formed from the inventive compositions are also provided, as well as processes and methods of manufacturing the inventive cross-linkable compositions and applications thereof.

The present invention includes transdermal delivery systems having a polymeric active agent reservoir fabricated from an admixture of polyisobutylene and an insoluble hydrophilic polymer in powdered form, which provide numerous advantages in the transdermal delivery of active agents using basic enhancer compositions. For example, the systems of the invention provide for (1) increased permeation of the active agent through the skin, (2) an improved capability of extracting the active agent and enhancer from the transdermal systems, (3) enhanced structural integrity, (4) good chemical stability, (5) reduced phase separation, and (6) decreased cold flow.

Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.

A pharmaceutical composition for preventing or treating chronic inflammatory airway diseases comprising alpha-enolase protein as an active ingredient is provided. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing chronic inflammatory airway diseases comprising alpha-enolase protein. The present invention further provides a composition for screening a therapeutic agent for chronic inflammatory airway diseases, comprising one or more of alpha-enolase protein or autoantibodies to alpha-enolase obtained from patients with chronic inflammatory airway diseases, and a method for screening a therapeutic agent for chronic inflammatory airway diseases using this composition. The present invention still further provides methods for diagnosing, preventing or treating chronic inflammatory airway diseases using alpha-enolase protein.

The invention provides improved methods and compositions for the treatment of cancer in a subject comprising administering to said subject a therapeutically effective amount of a composition comprising a chorionic gonadotropin or a therapeutically active fragment or analogue thereof in combination with an HMG CoA reductase inhibitor. The compositions and methods may also comprise geranylgeranyltransferase inhibitors (GGTI) and farnesyltransferase inhibitors (FTI) instead of or in addition to the HMG CoA reductase inhibitors of the invention.

Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

A composition for transdermal delivery of a non-traditional active agent is described. The compositions comprise: (a) a non-traditional transdermal active agent; (b) a solvent; (c) a non-miscible liquid; (d) a stabilizer; and (e) water, wherein the composition is formulated into an emulsion.

A skin disorder, a disorder associated with pain, fever, or inflammation, a proliferative disorder, or an ocular disorder is treated by topically administering a pharmaceutically acceptable formulation containing a therapeutically effective amount of a 4-phenylaminoquinoline compound.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

A self-contained voltage generating system is incorporated in a package or device for housing a product. There is at least one piezoelectric element incorporated in the package or device and the piezoelectric element generates a source of voltage when it is activated. The voltage is then used to perform various activities on other elements that are part of the package or device, such as operate a motor, provide heat, provide ultrasonic energy, furnish light, provide acoustic energy, and provide vibration energy. The piezoelectric elements are in the form of discrete particles, piezoelectric fibers, filaments, transducers, and actuators.

UV-photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane UV-sunscreen compound and at least one photostabilizing silicon-containing s-triazine compound substituted with two aminobenzoate or aminobenzamide groups.

The present invention comprises of a composition for post-hair-removal topical application for inhibiting mammalian hair growth & application thereof. The present invention also embraces a method of inhibiting mammalian hair growth by applying an effective amount of the composition to the skin. The composition comprises of a hair growth-inhibiting agent and a dermatologically acceptable vehicle.

This application relates to compositions and methods for inducing hair growth and improving hair quality utilizing extracts of Cotinus coggygria in an amount effective to induce hair growth when applied topically to an area of the skin on which hair growth is desired.

Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

The invention relates to a product for the targeted release of active substances, especially detergents and/or cosmetic active substances. The inventive product has a layer structure, one layer being impermeable to the active substance and another layer being permeable to the active substance. The two layers define a compartment between them which contains the active substance and optionally a gas-releasing component. The product is preferably suitable for single use and can be used as a cosmetic agent and/or as a cleaning agent.

The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.

The subject of the invention is a medicated product for local use based on natural materials which said product is suitable for alleviating respectively eliminating pain of different locomotor complaints of the body applying the product through the skin surface. The product according to the invention contains menthol in water solution, ethylene-diamine-tetra-acetic acid-alkali metal, salt (EDTA), furthermore in given case it contains carrier, diluter and/or other auxiliary substances applied in producing products for local use, characterized by that, the product contains essential oils furthermore non-ionic surface-active emulsifying agent and substances in the composition of the product as follows: Aethereum gerani 0.1 . . . 3 mass %, preferably 1.5 mass %, Aethereum rosmarini 0.1 . . . 2 mass %, preferably 0.5 mass %, Aethereum citri 0.5 . . . 3 mass %, preferably 1 mass %, Mentholum 0.1 . . . 3 mass %, preferably 1 mass %, EDTA 2Na 1 . . . 6 mass %, preferably 3 mass %.

The present invention is directed to novel capsules containing active material and nanoscaled material and to methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products.

Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.

Compositions are provided for lightening skin and toning down pigment disorders which include, as active substances, at least one of the compounds of the general formula (I) and/or salts thereof in which R.sup.1 is H, alkyl, hydroxyalkyl, or a carboxyalkyl radical having 2 to 30 carbon atoms; and R.sup.2 is H or a hydrocarbon radical having 1 to 30 carbon atoms which may be branched or unbranched and may or may not contain double bonds.

The present invention is related to octahydropyrrolo[2,3,c]pyridine derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

An article of manufacture containing polymeric microparticles, optionally loaded with an active agent, impregnated into a porous substrate is disclosed.

A medicament having an anti-wrinkle action, which comprises as an active ingredient a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid (for example, 4-(2,4-bistrimethylsilylphenylcarboxamide) benzoic acid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid, or the like).

The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent.

Use of anisic acid or a derivative thereof for promoting desquamation of the skin and/or for stimulating epidermal renewal. Associated compositions. Especially useful for improving the radiance of the complexion and/or the grain of the skin and/or for smoothing out the skin's microrelief, and/or for attenuating age spots.

The invention relates to a pharmaceutical composition, especially a dermatological composition, containing, in a physiologically acceptable medium, at least one compound of the avermectin family, and benzoyl peroxide, and also to its use for the manufacture of a medicament for treating skin conditions, especially rosacea.

The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and/or aesthetic appearance of skin.

The use of a substance belonging to the class of atypical retinoids for the topical treatment of acne is described. In particular the effects on an animal model for this skin disease of a pharmaceutical or cosmetic compound for topical use containing adamantyl methoxydiphenyl propenoic acid formulated in a gel are demonstrated.

The invention relates to a method, to a device and to uses thereof for the sensitive detection of audio events in order to obtain sensations and feelings of the living skin. The audio event is broken down in to several spectral ranges, and from the signals which represent said range, control voltages are determined for a defined selection of predetermined transmitters which act upon and/or in the living skin. The selection and allocation of the control voltages is dependant on a signal analysis which uses signals which represent the spectral range. The invention relates both to the rendering of deaf people sensitive to music and to the transmission of signals to deaf people.

The present invention provides methods and compositions for treating and/or preventing cancer in a subject via administration of a non-pathogenic virus. The present invention also provides methods and compositions for treating and/or preventing infectious diseases in a subject via administration of a non-pathogenic.

Kit for making up or non-therapeutically caring for keratin material(s), containing at least 0.01% by weight relative to the total weight of the composition of a moisturizer agent for improving the appearance of the keratin materials, at least two different compositions conditioned separately, the kit comprising at least one compound X and at least one compound Y, and at least one catalyst, with at least one of the compounds X and Y being a silicone compound, and the compounds X and Y being capable of reacting together via a hydrosilylation reaction in the presence of a catalyst, when they are placed in contact with each other,the moisturizer agent(s) being present in at least one of the two first compositions, or in a third composition separate from the first two.

The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents, or synthetic equivalents thereof, which inhibit or decrease expression of C-reactive protein expression, production or secretion, thereby reducing, inhibiting, or ameliorating dermatological signs of aging. The compositions of the invention may be topically applied to the skin, or are delivered by directed means to a site in need thereof, in an amount effective in improving the condition and aesthetic appearance of skin.

Provided are 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

The invention relates to the use of L-2-thiohistidine, or a cosmetically acceptable salt or ester of its acid group, as a depigmenting agent in a cosmetic composition or for the preparation of a cosmetic composition. It further relates to a method of cosmetic care for toning down or eliminating pigment spots on the skin and/or lightening the complexion by the application of this cosmetic composition. The invention provides a highly depigmenting composition.

The present application relates to a cosmetic composition comprising at least one carbonic acid ester corresponding to formula (I) below: R1--O--CO--O--R2 (I) in which R1 and R2 are identical or different and represent a linear or branched hydrocarbon-based radical, with the proviso that: when R1 and R2 are linear, they each contain from 1 to 6 carbon atoms, with 6.ltoreq.R1+R2.ltoreq.7; and when R1 and/or R2 are branched, they each contain from 1 to 8 carbon atoms, with 6.ltoreq.R1+R2.ltoreq.9. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

This invention provides new and novel devices and methods for administering lithium (Li) ions to a mammalian subject, especially the delivery of lithium (Li) ions to a body component for example across a body or tissue surface such as skin or a mucosal membrane, or for delivery of lithium ions directly to bodily fluids in a controllable and reproducible manner. In certain embodiments the device comprises a donor electrode that is a donor of a lithium ion; a protective architecture that is ionically conductive to the lithium ion, configured for application to a skin surface and positioned to isolate said donor electrode from the skin surface; and a counter electrode assembly configured for application to a skin surface, where said counter electrode assembly comprises a counter electrode operably coupled to said donor electrode.

A method and device for delivering active substances into and through the skin for treatment of the skin during and/or following fractional laser radiation treatment of the skin are described.

There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the color agent is one or more agents selected from the group consisting of a colored active agent, a colored indicator, a colored excipient, a pigment, a dye, a colorant and a coloring agent; b) a propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the base composition has a first color; and wherein the foam comprising the colored or colorable topical composition has a second color upon dispensing from an aerosol container, and wherein the first color and the second color are visually different. There is also described a method of changing color, a method of administration, a use as a diagnostic and a kit.

The present invention is related to the use of glyoxal-free compositions, more particularly, to the use of hydroxyethylcellulose agglomerated with low molecular weight hydroxyethylcellulose in consumer products, in particular, pharmaceutical, personal care (excluding oral care compositions), as well as household care applications.

The invention relates to a slimming cosmetic composition comprising, by way of an active agent, at least one inhibitor of metalloproteinases -2 and/or -9 or a plant extract containing said metalloproteinase inhibitor. The invention also relates to the use of an inhibitor of metalloproteinases -2 and/or -9 or a plant extract containing said inhibitor in a slimming cosmetic product. The invention further relates to the cosmetic use of an inhibitor of metalloproteinases -2 and/or -9 or a plant extract containing said inhibitor as an agent that prevents adipocyte differentiation for the preparation of a slimming composition.

In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35.degree. C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes.

Otitis externa is a condition of the outer ear canal in mammalian animals, especially dogs and cats, marked by inflammation and infection of tissue, buildup of ear wax, and draining of ear exudate. Symptoms of infection are, among others, excessive cerumen, alopecia in the ear flap, crusts, and ear pruritis. Typical causes of otitis externa are fungi, bacteria, and mites. A medicating mixture in accordance with the invention, comprising cold-pressed citrus oil, deionized water, and, optionally, hydrolysates of milk proteins, when applied topically to an infected ear canal can produce significant reduction in symptoms. In a clinical study, 95% of an infected population of dogs were normalized without other or further treatment.

The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

The glyceryl fatty acid monoester of octanoic acid, i.e. 1-glyceryl monocaprylate has, unlike other glyceryl fatty acid esters, such as 1-glyceryl monocaprate, been shown to inhibit cutaneous neurogenic inflammation. Therefore, this invention features uses and dermatological compositions of 1-glyceryl monocaprylate or analogues thereof for the treatment of cutaneous neurogenic inflammation, such as pruritus, pruritic skin disorders and seborrheic dermatitis, even without the need of co-administering other anti-inflammatory agents.

This invention relates to an implement 1 for applying a volume of liquid to a treatment surface. The implement includes a support means 3 onto which is mounted a receptacle 2, the receptacle defining a reservoir space 4 which receives the liquid. The receptacle includes a wall 6 having a working surface that is used to spread the liquid over the treatment surface. The wall 6 is resiliently deformable so in use the working surface maintains contact with the treatment surface when spreading the liquid. The implement has a specific application in applying a transdermal lotion to the axilla area of the user. The invention also relates to a system for transdermal administration of a physiological active agent from a liquid composition and a method of conducting the same.

Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.

Disclosed herein is a composition for make-up and/or care of the skin comprising a fatty phase, comprising: at least one resin of number average molecular weight less than or equal to 10,000 g/mol, selected from rosin, derivatives of rosin, and hydrocarbon resins, at least one hydrocarbon block copolymer, at least one fatty substance whose melting point is greater than 25.degree. C. chosen from waxes and pasty fatty substances, wherein said composition comprises less than 5% of volatile oil.

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

The present invention relates to the use of proteins of the UCP family, or UCP protein polypeptide or peptide fragments, as an active agent, alone or in association with at least one other active agent, in or for the preparation of a pharmaceutical and/or dermatological and/or cosmetic composition. The invention also relates to any composition containing the aforementioned active ingredient, as well as its use as a slimming agent.

A method for enhancing skin permeability by administration of a tetracyclic compound and improved methods for treatment of disorders by administration of a tetracyclic compound and a pharmaceutically active compound.

The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.

Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.

Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4.degree. C. and 40.degree. C.

Treating of localized bacterial infection, comprising locally applying Taurolidine to the infection. A device for insertion into the body, the device comprising Taurolidine to render the device infection resistant. A medication for treating bacterial infections, comprising Taurolidine carried by one of: gels, liquid, thixotropic gels, colloidal mixtures, dispensal suspensions, injectable polymers, or a microparticle. A method for treating blood, comprising: removing blood from the body; treating the blood with Taurolidine; and returning the treated blood.

Sunscreen compositions comprising one or more sunscreen agents (inorganic and combinations of inorganic and organic), one or more film forming polymers (synthetic or naturally derived), and heat treated xanthan gum. The sunscreen composition provides higher pre- and post-immersion SPF values, as well as a means for reducing the amount of sunscreen agents in a formulation without forfeiting efficacy.

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.

Composition containing, in a physiologically acceptable medium, a tensioning polymer and organic-mineral hybrid particles. Process, particularly for facial skin, in particular wrinkled skin, involving the application of the invention composition to the skin.

A personal care composition in the form of an oil-in-water emulsion is disclosed that provides improves skin feel. The personal care composition comprises from a silicone elastomer; a silicone fluid; a particulate material having a refractive index of less than about 1.8; a polymeric thickener; and water. The personal care composition may be substantially devoid of opacifying particulate material. A consumer product comprising the personal care composition is also disclosed. The consumer product allows for the application of the personal care composition to the skin or other keratinous tissue.

Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4.degree. C. to 40.degree. C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress .tau. for a given rate gradient .gamma. and which measure a rate gradient .gamma. for a given shear stress .tau., the yield value (.tau.0) being extrapolated visually or by calculation.

The invention relates to a cosmetic composition comprising the following as active agents: a first active agent consisting of an amber extract, and at least one other cosmetically active agent selected from the group consisting of extracts of Bertholletia excelsa, extracts of Potentilla erecta, magnesium aspartate, peptides acting on muscle contraction, particularly acetyl hexapeptide 3, peptides and their derivatives grafted with a fatty acid, particularly a C.sub.16 fatty acid, promoting collagen synthesis, particularly palmitoyl oligopeptide pentapeptide 3 or palmitoyl tetrapeptide 7, soy flour hydrolyzates and plant glycolipids, particularly cereal glycosphingolipids and more particularly wheat glycosphingolipids. It further relates to the use of an amber extract as a cosmetic agent acting on the dermal supporting proteins and/or the enzymatic systems that degrade the dermal proteins and/or the glycan-type essential components of the extracellular matrix, particularly proteoglycans, for improving the essential biomechanical properties of the skin, namely firmness and elasticity, in the preparation of a cosmetic composition.

Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring.

The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced by recombinant DNA technology.

The present invention provides a method of efficiently providing, to a client, a preparation for topical application and a supplement suitable for the client. This method entails inputting the part desired by the client to be improved and an improvement effect desired for the part into a system, which will determine the composition of nutritional components of a preparation for topical application and a supplement that are suitable for the improvement effect desired for the part to be improved by referring to a database, in which compositions of nutritional components of supplements are registered in advance.

The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.

The present invention relates to a cosmetic composition, in particular an anti-wrinkle composition, comprising, in a physiologically acceptable medium suitable for topical application to facial skin: (a) at least one tensioning agent chosen from: plant proteins and hydrolysates thereof, mixed silicates, colloidal particles of inorganic filler and synthetic polymers; and (b) at least one hydroxyalkyl urea of given formula. It also relates to the use of this hydroxyalkyl urea for improving the remanence of the tensioning effect afforded by a tensioning agent, and also to a process for treating wrinkled skin by applying to said skin a composition this hydroxyalkyl urea and a tensioning agent.

The invention relates to tissue filler compositions that are alterable or removable on demand. Also provided are methods for filling or augmenting tissue using the tissue fillers described herein, and correcting such tissue implants as required.

The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

Multi-part pharmaceutical formulations containing tetracycline for topical administration, as well as methods of making and administering the same, are disclosed.

Pharmaceutical formulations containing tetracycline for topical administration, as well as methods of making and administering the same, are disclosed.

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species through the bead structure, thus stabilizes the positively charged active ingredient inside the bead by impeding the interaction of the positively charged active ingredient and the catalytic species, and thereby extending the shelf life of the positively charged active ingredient.

Methods and devices for the non-thermal, electrically-induced temporary or permanent closure of blood vessels. The subject methods and devices employ pulsed electrical energy according to a defined regime to effect controlled occlusion of targeted blood vessels without heating the vessel and with minimal damage to adjacent tissue. The extent of vessel closure, i.e., temporary (vasoconstriction) or permanent (thrombosis), is controlled based on the manipulation of various parameters of the electrical stimulation regime as well as the configuration of the electrodes used to apply the regime.

The present invention relates to compositions and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the negative effects due to neuropathy.

The present invention relates to a composition for treating alopecia or promoting hair growth, which contains the blood plasma or serum as an active ingredient. The inventive composition is effective in hair growth, hair growth promotion and hair loss prevention.

A delivery system for topically applied compounds is disclosed. The delivery system contains a fatty acid, a phospholipid, and an oil, and is activated by the addition of water. The delivery system is admixed with a topically applied compound and water to provide a composition suitable for application to the skin or hair. The relative amounts of delivery system ingredients provide round, flexible vesicles that allow penetration of the topically applied compound to the epidermis and dermis, vesicles having a partially ruptured membrane for a controlled delivery of the topically applied drug to the epidermis and dermis, completely ruptured vesicles in the form of lamellar sheets that allow the topically applied compound to be retained in the stratum corneum, and mixtures thereof.

The invention relates to the use of compounds with certain sulfur and optionally nitrogen atom-containing structures as peroxide decomposers in cosmetic and pharmaceutical agents for treating the skin. The invention also relates to cosmetic and pharmaceutical agents comprising compounds having such structures.

The present invention relates to new heptaazaphenalene derivatives of general Formula (I) and to methods for obtaining them. The physicochemical properties of said compounds allow them to be used as UV radiation absorbents.

The present invention relates to an isoalkane mixture, to a method for its preparation and to cosmetic or pharmaceutical compositions which comprise such a mixture.

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system. In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I).

The present invention relates to a process for the preparation of tiliroside or tiliroside-containing extracts from parts of a plant selected from the Sterculiaceae family, to corresponding extracts, and to the use of the extracts or process products in cosmetics or topical applications.

The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition comprising paeoniflorin may become a very useful skin aging treatments.

The present invention is related to compounds having formula (I) wherein the dashed line indicates a single or double bond or is absent and wherein A.sup.1-A.sup.9, Q, R.sup.1-R.sup.11, T, U, V, W.sup.1-W.sup.3, X.sup.1, X.sup.2, Y and Z are as defined in the claims and description, pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament for the treatment of diseases involving abnormal cell proliferation, undesired cell proliferation, abnormal mitosis and/or undesired mitosis.

Stable, anhydrous pharmaceutical compositions contain an organopolysiloxane elastomer and, as bioactive ingredient, at least one vitamin D compound in a solubilized form, and are useful for the topical treatment of psoriasis and other skin disorders/afflictions.

The invention provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocaprolactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder wherein X is --CO--Y--(R.sup.1).sub.n or SO.sub.2--Y--(R.sup.1).sub.n; and Y is 0 cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or is 0 cycloalkenyl or polycycloalkenyl group.

The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).

2-Aminopyrimidine compounds are described, which are useful as H.sub.4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H.sub.4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

A cleanser composition composed of purified water, sodium laureth sulfate, zinc pyrithione, cocamidopropyl betaine, glycerol cocoate, polyquaternium-7, and a cross-linked polyacrylic acid polymer for topical application to an area affected by a skin disorder such as seborrheic dermatitis, perioral dermatitis, rosacea, acne, tinea versicolor, eczema and psoriasis.

Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.

A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.

A multi-ply technical composite, usable in particular for making medical aids, garments and medical articles, includes at least two layers (2, 3), the first of which (2), in contact with the skin, is a cotton fabric (elasticised to a greater or lesser extent) or silk, or fabrics to which chitosan, silver or another antibacterial substance or active constituent is added, and the second, outer layer (3) is constituted by a semipermeable membrane, such as polyurethane between 5 and 80 microns thick, with considerable elasticity in order to ensure the user's comfort. Receptors rechargeable with active constituents are inserted into fabric (2) and protected by the polyurethane membrane.

The invention is based on the discovery that the human protein referred to herein as INSP153 protein is a lipocalin.

The invention relates to a cosmetic composition comprising at least one aqueous phase and at least one antiperspirant active agent, characterized in that the said antiperspirant active agent consists of at least one flocculating water-soluble polymer comprising amine groups on the main chain and in that it does not contain any aluminium and/or zirconium antiperspirant salts. The present invention also relates to a cosmetic process for treating perspiration, which consists in applying to the surface of the skin an effective amount of such a composition. The present invention also relates to the use of a flocculating water-soluble polymer comprising amine groups on the main chain as an antiperspirant active agent in a cosmetic composition, and in particular in a cosmetic composition not containing any aluminium and/or zirconium antiperspirant salts.

The present invention is directed to the use of a compound selected from the group consisting of .beta.-carotene, lutein, lycopene and .beta.-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods. The present invention is further directed to the use of a compound selected from the group consisting of .beta.-carotene, lutein, lycopene and .beta.-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 in sunscreens as well as daily care products to improve their photoprotective potential, as well as to their use as effective micronutrients for skin maintenance. Furthermore the present invention is directed to compositions, preferably orally applicable compositions, comprising a certain amount of at least one compound selected from the group consisting of .beta.-carotene, lutein, lycopene and .beta.-cryptoxanthin and mixtures thereof and combinations thereof with CoQ-10 as active ingredient, characterized in that the amount is effective for such uses as mentioned above.

Moisture of the skin, skin lipid balance and skin smoothness can be improved by administering an oral composition containing, as active ingredients, proteins and/or protein hydrolysates wherein the total proteins and hydrolysates contain at least 2 wt. % of cysteine residues. Preferably, the hydrolysates have an average molecular weight of between 200 and 4000 Dalton. The composition is administered in such an amount that between 25 and 500 mg of cysteine per day is supplied.

Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

The present invention relates to cosmetic and pharmaceutical compositions which comprise a copolymer with anionogenic and/or anionic groups which is obtainable by free-radical polymerization of a monomer mixture in the presence of a polyfunctional regulator with at least three functional regulating groups. The invention further relates to a method of producing such a copolymer and to the copolymers obtainable by this method.

A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.5% to about 15% by weight; water; an effective amount of an active pharmaceutical agent having a degree of solubility in the emulsion composition; and at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the unctuous emollient comprises a petrolatum alone or in combination with other unctuous agents; wherein the multi active agent is selected from the group consisting of (a) two or more complex emulgators wherein there is a difference of about 4 or more units between the HLB values of two of the emulgators or there is a significant difference in the chemical nature or structure of two of the emulgators; (b) a surfactant and a foam adjuvant or co surfactant, wherein the surfactant has a HLB close to the required HLB of the oil phase; (c) a surfactant and a liquid wax, wherein the surfactant has a HLB close to the required HLB of the oil phase; (d) a surfactant and a polymeric agent other than starch or a modified starch ester, wherein the surfactant has a HLB close to the required HLB of the oil phase; (e) a polymeric agent and a foam adjuvant or co surfactant, which can cooperate to stabilize the emulsion; (f) a single surfactant without a long polymeric side chain that is composed of a mixture of esters having a HLB close to the required HLB of the oil phase; combinations of any of the above, and wherein the composition is substantially flowable is stored in an pressurized container and upon release expands to form a breakable foam.

The present invention relates to continuous spray medications involving the scalp, such as minoxidil, finesteride, copper peptides, DHT inhibitors and androgen receptor blockers, for example, in an amount sufficient to stimulate or maintain hair growth. The scalp medication is disposed within a pharmacologically acceptable carrier solution. In further embodiments, the spray scalp medication is dispensed within a product bag containing the medication in liquid form. The product bag is disposed within a container and includes a sheet of gas impervious material having a barrier layer therein. A gaseous propellant is also disposed within the container and is substantially separated from the medication. The valve assembly is selectively operated to produce a fine mist of said medication which is non-chilling, continuous and even.

The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.

The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition.

Single-use personal care products and kits comprising the same are disclosed. At least some of the single-use products include a pre-measured amount of a shaving composition.

Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier.

The present invention relates to a composition for the skin whitening and wrinkle improvement, comprising an extract of Vaccinium uliginosum as an active ingredient. The Vaccinium uliginosum extract has the effects of inhibiting and scavenging reactive oxygen species produced in skin tissue as a result of ultraviolet irradiation to the skin, effectively inhibiting tyrosinase activity to inhibit the production of melanin in melanin cells, inhibiting the secretion of cytokines in keratinocytes, promoting the production of procollagen, and inhibiting the decomposition of collagen. Thus, the extract will be useful for the prevention of skin photo aging caused by ultraviolet radiation, the enhancement of skin whitening and the improvement of wrinkles. In addition, the Vaccinium uliginosum extract is suitable to use as a component for improving skin wrinkles in cosmetics, foods and drugs, because the Vaccinium uliginosum extract can achieve the effect of improving skin conditions, even when it is applied to the skin or used internally.

A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.

Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

A cosmetic combination product, wherein the product comprises at least two components selected from (a) one or more dietary supplements, (b) one or more cosmetic preparations for topical application to human skin, and (c) one or more patches for adhesion to human skin. Each of the selected components (a) to (c) comprises at least one cosmetically active substance which is also comprised in the other selected component(s). This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

A subject-matter of the invention is a cosmetic method for caring for wrinkled skin, for the purpose of softening the wrinkles, comprising the successive stages: (a) of topical application to the wrinkled areas of a first composition including a pulverulent phase comprising porous particles which comprise at least one antiwrinkle active principle at least partially absorbed in the said particles, the said composition being substantially devoid of solvent for the said active principle, and (b) of topical application to the skin of the face comprising at least the said areas of a second composition including a fatty and/or aqueous phase comprising a solvent for the said active principle.

This invention relates to antimicrobial wound dressings having a non-leaching antimicrobial activity, releasable antimicrobial and antiprotease agents, and a controlled-release bioactive agent such as doxycycline. The Wound dressing material is absorbent and acts as a substrate for antimicrobial and antiprotease agents as well as bioactive agents. More generally, this invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymeric molecules and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy. Utilization of non-leaching coatings having a plurality of anionic or cationic sites is used according to this invention to bind a plurality of oppositely charged biologically or chemically active compounds, and to release the bound oppositely charged biologically or chemically active compounds from said substrate over a period of time to achieve desired objectives as diverse as improved wound healing to reduction in body odor.

The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

The invention provides a method comprising the steps of: (i) providing an emulsion of: a) an aqueous solvent, such as water, b) a carrier material dispersible or soluble in (a), said carrier material being solid at ambient temperature, and preferably being a polymer and inorganic salt or a surfactant, c) a volatile second liquid phase (for example, chloroform) which is not miscible with (a), and d) a material which is dispersible or soluble in (c) but not in (a), and, (ii) Drying the emulsion at above ambient temperature (preferably by spray drying) to simultaneously remove (a) and (c) and thereby obtain the material (b) in solid form with (d) dispersed therein.

Personal care composition comprising at least one extract selected from the group consisting of extracts of Terminalia bellerica, Butea monosperma, Mallotus philippinensis, Anogeissus latifolia, Innula racemosa, Ficus benghalensis, Nerium indicum, Psoralea corylifolia, Acacia catechu, Abies pindrow, Cedrus deodara, Emblica officinalis, Moringa oleifera, Glycyrrhiza glabra, and mixtures thereof, and a dermatologically acceptable carrier. Additionally or alternatively, the composition may comprise 2-hexyldecanol.

A topical formulation comprising as active ingredients, at least one effective agent derived from Streptomyces avermitilis, i.e. a macrocylic lactone e.g. an avermectin or chemically modified or synthetic derivative thereof, e.g. ivermectin, together with another anthelmintic of the sulphonamide type, e.g. clorsulon, in a carrier that facilitates topical administration and delivery of the active ingredients transdermal Iy, e.g. a carrier that is useful for this purpose comprises alcoholic solvents, such as ethanol, and isopropanol, with optional excipients and formulation aids, which may comprise a polymeric species such as PVP or a poloxamer.

The invention relates generally to the use of anti-sense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5.alpha.-reductase gene and thereby modulate levels of dihydrotestosterone (DHT). Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia. The invention specifically relates to formulations of these anti-sense oligonucleotides, small interfering RNA, and ribozymes for administration to treat and prevent disorders

The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.

The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder.

A compound of formula (I):wherein A represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; and R.sup.1 and R.sup.2 each independently represent hydrogen, fluorine or chlorine; or a physiologically functional derivative thereof.

The present invention provides new topical pharmaceutical or cosmetic compositions for the prevention and treatment of irritation of mucous cells, or skin cells, comprising a combination of: xylitol, myoinositol or mannitol or any combination of these; glycerol and/or urea; water; in the absence of any oil in water or wax in water emulsion.

This invention relates to the field of polymeric materials that can be used in combination with a wide variety of substrates, such as personal care products, textiles, metal, cellulosic materials, plastics, and the like, and to the field of active agents including, for example, antimicrobial, antibacterial and antifungal materials. This invention further relates to latex polymer coatings that comprise at least one active component as well as methods for making and using such latex compositions.

Combinatorially generated peptides are provided that have binding affinity for Polytetrafluoroethylene (NY). The peptides may be used to deliver benefit agents to various PTFE surfaces.

Methods of treating tissue with fractional laser radiation are disclosed. The fractional laser treatment methods reversibly increase skin permeability while maintaining a substantially intact stratum corneum and producing alterations within the epidermis and dermis. The alterations in the epidermis and dermis can include necrosis and/or coagulation. The alterations in the epidermis can include the creation of a plurality of pores in the stratum corneum and/or the creation of vacuoles in the layers of the epidermis below the stratum corneum. The fractional laser treatment methods disclosed herein can be used to provide treatments to the skin, to increase permeation of active substances into or through tissue, to deliver active substances locally or systemically, and to control the delivery of active substances.

The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.

Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.

A preparation and method for treating a subject how had developed or is at risk of developing at least one of high blood pressure, Alzheimer's Disease, obesity, and Diabetes Type II, Sickle Cell Anemia, Preeclampsia, Sudden Infant Death Syndrome, or Vascular disease comprising positioning ammonia oxidizing bacteria close proximity of a surface of the subject, of nitric oxide and nitric oxide precursors using ammonia oxidizing bacteria.

The invention provides methods for preventing and/or treating itch in a subject in need thereof by administration of a protease-activated G-protein coupled Protease Activated Receptor 4 (PAR4) antagonist. The PAR4 antagonist can be combined with a PAR2 antagonist.

The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases.

The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer.

The present invention relates to a flavor composition or fragrance composition which can satisfy diversified requirements for flavored products, as well as to a flavor-improving agent which can improve the quality and release of aroma of a beverage or food. More particularly, the present invention relates to a flavor composition or fragrance composition which comprises an optically active S-alkyl 2-methylbutanethioate as an active ingredient, a flavor- or fragrance-added product, a flavor-improving agent which comprises an optically active S-alkyl 2-methylbutanethioate as an active ingredient, and a beverage or food having an improved flavor. The optically active S-alkyl 2-methylbutanethioate includes S-alkyl (R)-2-methylbutanethioate and S-alkyl (S)-2-methylbutanethioate.

Aqueous washing and cleaning agents that contain capsules in addition to other constituents, the capsules each encompassing an active ingredient in a matrix. The introduction of a combination of aluminum silicate and silicic acid into the matrix improves the solubility characteristics of the capsules in a washing operation.

This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

The present invention relates to a pharmaceutical composition for the prevention or treatment of diseases mediated by excessive histamine comprising naturally-derived isoorientin, a use of isoorientin for the manufacture of a medicament for the prevention or treatment of diseases mediated by excessive histamine, and a method for preventing or treating diseases mediated by excessive histamine comprising administering a therapeutically effective amount of isoorientin to a subject. The composition, use and method of the present invention show excellent histamine suppression effects, and so can be used for the prevention or treatment of various kinds of allergic disease, atopic disease, inflammatory disease, skin disease, hyperacidity and nervous system disorder.

An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy groups, like a monoC.sub.1-4alkyl ether of an ethylene glycol or a monoC.sub.1-4alkyl ether of a propylene glycol oligomer, and/or a silicone fluid.

An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face. Each electrically conductively engages the skin, when the substrate is retained thereon. A power source carried on the substrate is electrically coupled between the medicament matrix and a programmed microprocessor also carried on the substrate. A substantially invariant voltage presented at an output contact of the microprocessor is applied during a predetermined therapy period across the skin between the medicament matrix and the return electrode, inducing transcutaneous migration of medicament into the skin at a substantially constant rate. A light-emitting diode carried on the substrate and coupled to the microprocessor communicates that the patch is operating.

Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20.degree. C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second.+.0.02 seconds.

The invention concerns the cosmetic use of at least one 2-alkyl furan, as depigmenting active principle, in a depigmenting composition, as well as the associated cosmetic treatment method. The invention also concerns the use of at least one 2-alkyl furan for preparing an active drug as depigmenting agent. The invention further concerns a depigmenting cosmetic composition comprising as depigmenting active principle at least one 2-alkyl furan.

A composition comprising; water purified using ozonation, ionization, or distillation or any combination thereof wherein alcohol may be substituted for, or combined with water; at least one emollient including but not limited to chitosan, and aloe vera gel, individually or in any combination; an oil component with spf boosting agents including but not limited to; silicone oil and essential oils, butter milk, waxes impregnated with inorganic sun-block or sunscreen agent and organic/inorganic micronized particles, wood powder and bentonite clay, keratin, either individually or in any combination; at least one inorganic sun-block or sunscreen agent including any metal oxide, glass microsphere, silica and silica compound, and optionally metal oxide pigments with particles that are micronized, submicronized, nanoparticle sized, or otherwise individually or in any combination that can be homogenized in either a water phase, a water-aloe phase, or an oil phase or any phase of the composition; at least one emulsifier such that the emulsifier includes but is not limited to a phospholipid and/or liposome or an aloe vera gel or an ester of coconut oil individually or in any combination, for emulsification of the water, water-aloe, and/or the oil phases. Any of components are preferably mixed using an homogenizer and an appropriate thickening agent including but not limited to xanthan gum, and/or carageenan, either individually or in any combination that is added as required.

Disclosed are compositions for solubilizing and/or removing a hair styling aid composition from hair. The compositions comprise at least one active solvent, wherein the active solvent is a glycol or an ester; and a carrier composition comprising a liquid vehicle. Also disclosed are methods for solubilizing and/or removing hair styling aids from hair.

This invention relates to a system comprising nanoparticles designed for the release of biologically active molecules, where the nanoparticles comprise a) at least 40% by weight of chitosan or a derivative thereof and b) less than 60% by weight of a cyclodextrin or a derivative thereof, where both components a) and b) are mixed, without any covalent bond between them. This system allows for the efficient association of biologically active molecules, as well as their subsequent release in a suitable biological environment.

The present invention relates to dermocosmetic compositions comprising a compound comprising the structural element of the formula I where the radical Z has the following meaning: H, C.sub.1-C.sub.22alkyl group, C.sub.6-C.sub.10-aryl group, C.sub.1-C.sub.22-alkoxy group or a C.sub.6-C.sub.10-O-aryl group substituted by a C.sub.1-C.sub.22-alkyl or C-C.sub.22-alkoxy group, and the radicals R.sup.1 to R.sup.6, independently of one another, have the following meaning: H, C.sub.1-C.sub.22-alkyl group, C.sub.6-C.sub.10-aryl group, O, OH, C.sub.1-C.sub.22-alkoxy group or a C.sub.6-C.sub.10-O-aryl group substituted by a C.sub.1-C.sub.22-alkyl or C.sub.1-C.sub.22-alkoxy group, it being possible for R.sup.5 and R.sup.6 to be bridged in such a way that a five- to eight-membered ring is formed and, in the case of a five-membered ring, this ring may be part of an oligomer as a result of covalent bonds at positions 3 and 4. The invention furthermore relates to the use of said compounds in dermocosmetic formulations and the use of the dermocosmetics according to the invention for reducing skin or hair damage caused by free radicals. The invention furthermore relates to the use of the compounds according to the invention for increasing the stability of dermocosmetic formulations.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

The present invention is directed to novel compounds according to formula (I) wherein R.sub.1, R.sub.2, and X are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents for the treatment of cancer, diabetes, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.

The present invention relates to compounds of the formula (I): including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.

The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor.

The invention provides a method for preparing water dispersible or water soluble porous bodies and the bodies themselves The bodies have an intrusion volume as measured by mercury porosimetry of at least about 3 ml/g and comprise a three dimensional open-cell lattice containing less than 10% by weight of a water soluble polymeric material and 5 to 90% by weight of a surfactant, with the proviso that said porous bodies are not spherical beads having an average bead diameter of 0.2 to 5 mm. The method comprises the steps of: a) providing an intimate mixture of the polymeric material and the surfactant in a liquid medium b) providing a fluid freezing medium at a temperature effective for rapidly freezing the liquid medium; c) cooling the liquid medium with the fluid freezing medium at a temperature below the freezing point of the liquid medium for a period effective to rapidly freeze the liquid medium; and d) freeze-drying the frozen liquid medium to form the porous bodies by removal of the liquid medium by sublimation.

The invention relates to a method for body shaping by means of a sun-protection agent and a corresponding cosmetic product. The inventive method consists in pre-treating by means of a preliminary product containing a caffeine, algae extract, pineapple extract, radical scavenger, copper gluconate, silylpropionic acid and a melanin-stimulating amino acid-containing agent, in subsequently treating by a main product containing, apart from an UVA- and UVB-Filter, at an ratio ranging from 30:70 to 70:30, a green coffee bean oil whose radical scavenger content is 30-60% less than this of the preliminary agent and in post-treating by means of an after-product which comprises the preliminary product constituents and whose silylpropionic acid content is of 2 to 10 times the content of the preliminary product.

A composition based on labdane-diterpenoids that provides better photo protection against both UV A and UV B radiations in the HaCaT human keratinocyte cell lines is disclosed. The composition comprises 8,13-epoxy-1.alpha.,6.beta.,7.beta.,9.alpha.-tetrahydroxylabd-14-en-11-on- e alone and in combination with 6.beta.-acetoxy-8,13-epoxy-1.alpha.,7.beta.,9.alpha.-trihydroxylabd-14-en- -11-one and/or 7.beta.-acetoxy-8,13-epoxy-1.alpha.,6.beta.,9.alpha.-trihydroxylabd-14-en- -11-one. The composition protects the cells of the skin from harmful UV A and UV B rays through synergistic mechanisms with utility as a safe long-term cosmetic solution for preventing UV-induced skin damage and to induce sunless tanning. Additionally, the composition enhances melanogenesis in B16F1 mouse melanoma cells acting as tanning inducers/accelerators both in the presence or absence of sunlight. Elevation of melanogenesis confers additional protection against UV-induced skin damage.

This invention relates to a novel protein, termed INSP162, herein identified as a secreted protein containing c1q and collagen domains and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

The present invention includes compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles.

Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections (3) extending from a substrate; applying the array of micro-projections to an area of skin to form an array of microscopic holes therein; and contacting the area of skin with a transdermal composition comprising a physiologically active agent and at least one penetration enhancer wherein the formation of the microscopic holes and penetration enhancer facilitate transdermal delivery of the physiologically active agent.

The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein polymer having bioactivity.

Processes are disclosed for preparing silicone vesicle compositions and emulsions containing silicone vesicles, the compositions prepared therefrom, and formulated personal and healthcare products containing the silicone vesicles and emulsions compositions.

Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry of at least 3 ml/g.

Particles are provided for use in restorative procedures to treat erectile dysfunction. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be loaded to provide localized treatment with an active agent directed at restoration of normal penile erectile function and the treatment of erectile dysfunction. Moreover, such particles may be provided to a user with customized coloration or in various coded colors to indicate differing doses of active agent contained therein.

The present invention provides a particle comprising at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto. The particle of the invention may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms.

The present invention encompasses CXCL13 binding proteins. Specifically, the invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for CXCL13 and CXCL13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting mouse CXCL13 and for inhibiting mouse CXCL13 activity, e.g., in a mammal suffering from a disorder in which CXCL13 activity is detrimental.

The invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders, and uses compounds of general formula (I) or a pharmaceutically acceptable salts thereof; whereinX is --CO--R.sup.1 or --SO.sub.2--R.sup.2, and R.sup.1 and R.sup.2 are carbonaceous substituents.

The invention relates to a compound of formula (I), or a pharmacologically or cosmetically acceptable salt or derivative thereof, wherein R.sub.1 to R.sub.5 are selected from the groups R.sub.1 representing -alkyl, -vinyl, --CHOH--CH.sub.2OH, R.sub.2 representing H, --OH, --Oalkyl, --Oacyl, saccharide groups, modified saccharide groups (e.g. malonylated), R.sub.3 representing --H, --OH, --Oalkyl, --Oacyl, modified --Oacyl (e.g. malonylated), saccharide groups, modified saccharide groups (e.g. malonylated), R.sub.4, R.sub.5 representing --COOH, -carbonic esters, for use as drug, antioxidant, food supplement. The invention also relates to a method for producing the compound of formula (I).

Systems and methods for transdermal drug delivery with controlled heat are provided. Such systems can comprise a heating apparatus that includes an exothermic chemical composition, typically in the form of individual heating elements. The heating apparatus can be exposed to ambient oxygen through a cover. The cover can reduce the amount of ambient oxygen capable of contacting the chemical composition compared to when the cover is not present. In some embodiments, the heating apparatus can include more than one heating element. The systems can further include a drug-containing layer that includes a drug. The drug-containing layer can have a surface area of about 50 cm.sup.2 to about 400 cm.sup.2. The systems of the present invention can be deliver ketoprofen in an amount sufficient to produce a mean blood plasma concentration of ketoprofen in a human subject of at least 45 ng/ml within four hours after initial application of the system to a skin surface.

Provided are methods of simulating tissue healing. The methods comprise using a mechanistic computer model of the interrelated effects of inflammation, tissue damage or dysfunction and tissue healing to predict an outcome of healing of damaged tissue in vivo, thereby predicting the outcome of healing of damaged tissue in vivo. Implementations of these methods on a computing device also are provided. Non-limiting examples of diseases and/or conditions that are amenable to simulation according to the methods described herein include: a diabetes, diabetic foot ulcers, necrotizing enterocolitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, restenosis (post-angioplasty or stent implantation), incisional wounding, excisional wounding, surgery, accidental trauma, pressure ulcer, stasis ulcer, tendon rupture, vocal fold phonotrauma, otitis media and pancreatitis.

This invention relates to the field of polymeric materials that can be used in combination with a wide variety of substrates, such as textiles, metal, cellulosic materials, plastics, and the like, and to the field of active agents including, for example, antimicrobial, antibacterial, and antifungal materials. This invention further relates to latex polymer coatings that comprise at least one active component as well as methods for making and using such latex compositions.

The invention relates to a clear, cosmetic and dermatological formulation having reduced stickiness, comprising at least one antiperspirant active ingredient and/or deodorant active ingredient, at least one .alpha.-hydroxycarboxylic acid and water.

A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

It has been discovered that vascular endothelial growth factor ("VEGF") promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the "wounded skin" phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles.

The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof by administering to the mammal a composition containing eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof, alone or in combination with other active ingredients.

It is intended to provide a substance which is efficacious in whitening sun-burnt skin after UV irradiation and preventing, ameliorating and treating skin pigmentation (for example, spots and freckles caused by sunburn, liver spots) and compositions containing the same. Melanogenesis inhibitors and whitening agents comprising an ergosterol derivative represented by formula (1); melanogenesis inhibitors and whitening agents containing the ergosterol derivative represented by the formula (1); melanogenesis inhibitory compositions and whitening compositions containing the ergosterol derivative represented by formula (1); cosmetics, drugs and external skin preparations containing the ergosterol derivative represented by formula (1); and melanogenesis inhibitory foods and whitening foods containing the ergosterol derivative represented by formula (1).

The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one PDGF receptor tyrosine kinase inhibitor.

The present invention relates to novel compounds of formula (I), processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

The invention relates to a formulation comprising an aqueous emulsion and a propellant gas for a foam skin cream, wherein the emulsion comprises urea and hyaluronic acid, at least one free fatty acid and at least two emulsifiers, wherein the hyaluronic acid has a molecular weight of at least 1.times.10.sup.5 Da.

A novel method is disclosed for the preparation of oil-in-water emulsions suitable for cosmetic or topical dermatological products. The method comprises the step of mixing at least one cosmetically active ingredient with an aqueous emulsion of washed vegetable oil bodies (oleosomes) and the temperature of the products does never exceed about 40.degree. C. during the steps of the method.

An aqueous based antiperspirant/deodorant composition comprising (a) an antiperspirant active ingredient; (b) at least one water absorbing polymer pretreated with a non-aqueous polar solvent; and (c) water, wherein the pretreated water absorbing polymer inhibits the water absorbing properties of the polymer in the aqueous based composition prior to application to the skin.

Deodorant or antiperspirant sticks based on an oil-in-water dispersion/emulsion for application on the skin.

The invention provides an epidermal basement membrane structure formation accelerating preparation and a skin external preparation comprising a serine protease inhibitor, and optionally an accelerator of production of extracellular matrix protein components of the epidermal basement membrane. It also provides, as a means for producing artificial skin having an adequately formed basement membrane, an artificial skin-forming medium which comprises a serine protease inhibitor, and optionally an accelerator of production of extracellular matrix protein components of the epidermal basement membrane and a matrix metalloprotease inhibitor, as well as a method for producing the same.

The present invention relates to a wetting solution for manufacturing wet wipes or other wet flexible materials, and to such wet wipes for cosmetic, body care, dermatological and/or cleaning purposes, such as cleaning wipes, facial cleaning wipes, make-up remover wipes, refreshment wipes, baby wipes, wet toilet paper or eyeglass cleaning wipes, wherein the preferably aqueous wetting solution contains at least one amino acid ester, preferably from the group of pyrrolidone carboxylic acid esters, as an emulsifier. The invention further relates to the use of such amino acid esters as emulsifiers in wetting solutions for manufacturing said wet tissues.

The present invention provides hydroxamic acid derivatives represented by the formula, having antioxidation, collagen biosynthesis promotion and skin pore contraction effects, and a method for preparation thereof. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula as an active ingredient.

Improved aqueous foaming topical compositions for the application to the human body particularly to the skin which composition provides both a cleaning benefit, and a durable antimicrobial benefit.

The invention describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, in a composition for non-medical treatment of the skin, for example as a deodorant. The invention also describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, for manufacturing of a pharmaceutical preparation for treatment of skin related conditions and diseases, as skin infections. The hydrophobic zeolite is especially selected from that group that comprises silicalite, or hydrophobic ZMS-5, hydrophobic mordenite and hydrophobic zeolite Y.

Substantially homogeneous topical preparations for cosmetic, veterinary, and pharmaceutical use comprise at least one active ingredient solubilized in a novel composition base. The composition base comprises solubilized allantoin at a level of at least 0.5% and urea at a level of at least 10% in an aqueous vehicle.

The present invention relates to a hyaluronidase inhibitor containing poly-gamma-glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization and skin elasticity by effectively inhibiting the activity of hyaluronidase which is an enzyme that degrades hyaluronic acid present in the skin dermis. Also, the compositions can relieve allergic symptoms by inhibiting the permeability of inflammatory cells.

The present invention relates to a DNA vaccine consisting of a vector expressing a part or the whole of a polypeptide regulating production of an inflammatory cytokine, a pharmaceutical composition comprising the DNA vaccine, and a method of preventing or treating an inflammatory disease by using the pharmaceutical composition.

The invention concerns particles consisting essentially of fibers of an organogelling substance in the form of xerogel (dry gel), the fibers being essentially oriented in a common direction and randomly aligned around the longest fiber. The organogelling substance is preferably 1,3:2,4-di-O-benzylidene-D-sorbitol. Said particles, which are in the form of spindles, have interesting optical properties; they have a total light transmittance higher than 0.80, with a diffuse transmittance higher than the specular transmittance. The invention also concerns a method for preparing said particles by solvent evaporation process, by solvent diffusion/evaporation process or by shearing process. The invention finally concerns active particles consisting of said particles whereon is immobilized a dermocosmetically active principle, a dermocosmetic composition comprising said particles or said active particles and a cosmetic treatment method which consists in applying on the skin said dermocosmetic composition.

The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.

Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin.

Compositions of all-trans-retinol: all-trans-13,14-dihydroretinal saturase and methods of use thereof are provided.

The object of the invention is an active principle derived from a powder of alfalfa seeds (Medicago sativa) permitting counteracting, in a manner similar to retinol, the phenomenon of extrinsic aging of the skin, with anti-wrinkle and smoothing properties. The invention also covers the active principle, the procedure of obtaining the same, and the compositions including it.

This invention relates to the preparation of veterinary anthelmintic formulations including triclabendazole in solution, particularly for the treatment of parasitic infections such as fasciolisis, and particularly for administration to an animal in the form of a pour-on. The solutions may include triclabendazole dissolved in a solvent system including at least one solvent selected from 2-pyrrolidone and liquid polyethylene glycol. Additional solvents may also be included. The present invention is advantageous as triclabendazole can be included in solution up to a concentration of about 60% w/v allowing for an effective dose to be delivered to the animal in a volume of 25 ml or less.

The present invention provides a non-naturally occurring lipoprotein nanoplatform ("LBNP") comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs.

This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface, upon application. More particularly, the invention relates to foamable compositions comprising: (a) a foamable carrier; (b) at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; stimulating or refreshing agent; or mixtures thereof and (c) a propellant at a concentration of about 3% to about 45% by weight of the total composition. The foamable carrier can be an emollient emulsion foamable vehicle, a foamable gel vehicle and can also be a substantially non aqueous foamable vehicle.

Disclosed are personal care compositions, including compositions for oral, throat and skin care comprising a blend of naturally occurring flavor or perfume ingredients or essential oils containing such ingredients, wherein the blend provides excellent antimicrobial activity and comprises at least two components, a first acyclic component selected from citral, neral, geranial, geraniol and nerol and a second cyclic-containing component selected from eucalyptol, carvacrol and eugenol. Preferably, the blend comprises 3, 4, 5 or more of the above components. Greater synergy in terms of antimicrobial efficacy may be obtained the more different components are blended together. The present compositions are effective in killing, suppressing the growth of and/or altering metabolism of microorganisms including those which cause undesirable oral cavity conditions including plaque, caries, calculus, gingivitis, periodontal disease and malodor. Optionally the blend further comprises additional antimicrobial and/or anti-inflammatory components, preferably naturally-occurring as well.

The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation.

Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.

The invention is based on the discovery that the human protein referred to herein as INSP181 protein is a lipocalin.

Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic acid phenethyl ester, delphinidin, ethyl abietate, esculetin, sorbic acid methyl ester, canaline, N-formyl-methionine, N-formyl-alanine, taurine, palmitoyl carnitine, undecanol, undecylenic acid, rutin, fusidic acid, phenyl pyruvic acid, L-isoleucine, phenyl glycine, silibinin, silymarin, L-ascorbic acid-6-palmitate, N-undecylenoyl-L-phenylalanine, and salts, derivatives and mixtures of any of the foregoing; and a dermatologically-acceptable carrier.

A composition comprising a content of a lysozyme and a content of a C-1/C-4 polysaccharide is useful in oral care, cosmetology and dermatology, contraception, urology and gynecology. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR .sctn. 1.72(b).

The present invention relates to the use of Pirlindole, if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Pirlindole and use thereof.

The present invention relates to a method for treating a subject for a condition or inflammation associated with oedema, excess body fluids or oedema and excess body fluids, or for treating a subject for an abscess, boil, blister or cyst. The method comprises applying to the skin surface covering a body part or region affected by said condition, inflammation, abscess, boil, blister or cyst a composition capable of transdermally attracting fluids from the body part or region or its proximity, wherein said composition comprises at least one adsorptive or absorptive agent, and leaving said composition in contact with the skin for sufficient time to allow said composition to transdermally absorb or adsorb at least a portion of the body fluids from said body part or region. The present invention also relates to compositions for absorbing or adsorbing fluids from a body part or region, and which are capable of transdermally attracting fluids from body parts or regions or their proximity.

Botanically-sourced and botanically-derived emollient sanitation compositions for topical use are disclosed. Representative compositions generally aid reconstitution of the lipid profile of the stratum corneum by providing botanical lipids and/or lipid-derivatives that resemble human sebum--these components being ordinarily diminished with the use of conventional hand sanitizer products. Disclosed features and specifications may be variously controlled, adapted or optionally modified to realize, for example, improved hand sanitizer formulations. Representative embodiments of the present invention generally provide anti-microbial compositions blended with botanically sourced lipids and/or lipid-derivatives to control or otherwise improve dermatitic symptoms associated with frequent use of conventional hand sanitizer products.

This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naph- tho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naph- tho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-.alpha.) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions. The invention relates to inhibition of the expression of intercellular adhesion molecule 1 (ICAM-1), vascular-cell adhesion molecule 1 (VCAM-1), and E-Selectin by the said compositions. The said compositions may optionally contain at least one anti-inflammatory agent or can be used in combination with at least one anti-inflammatory agent.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.

The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).

The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.

The invention concerns methods of treating or preventing the effects of irradiation in a human or non-human animal using carotenoid compounds, preferably diadinoxanthin, diatoxanthin and/or fucoxanthin as well as photoprotective compositions and their use to prepare photoprotective or photoprotected products.

The invention relates to the cosmetic use, especially for the cosmetic treatment of keratin materials, of amphoteric polysaccharide compounds containing cationic polymer chain(s), which may be obtained by grafting and polymerization of ethylenic monomers of formula (I), Q.sup.- onto an anionic polysaccharide of formula (II): in the presence of a catalytic system based on potassium permanganate (KMnO.sub.4) and sulfuric acid (H.sub.2SO.sub.4). The invention also relates to compositions comprising at least one cosmetic active agent and at least one of these amphoteric polysaccharide compounds, in a cosmetically acceptable medium.

The use of depolymerized scleroglucan alone, or in combination with one or more active ingredients as a moisturizer, and as anti-inflammatory active ingredient for protecting and for restoring a healthy skin barrier in the field of cosmetic or dermatological skincare is disclosed.

An emollient component is provided in a composition, suitable for topical application to skin, comprising a fugitive solvent base comprising at least one alcohol. One advantage of the invention is that the irritancy potential of the composition due to the alcoholic fugitive solvent base is reduced.

Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion.

Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Method for preparing an active-containing starch matrix and the free flowing, dry powder that results from such a process. The active ingredients can be released (deposited) onto a surface by normal triggering mechanisms, which include the action of a liquid or by friction or rubbing. The fixative systems described herein provide the ability to control high load levels and protection of the active while still being able to delivery this to a substrate when triggered. Additionally, ingredients incompatible and reactive with each other can be blended together as sold/used as a one piece system and no reactions will occur until the matrix is broken or triggered.

The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method of manufacturing same.

Device for smoothing wrinkles on human skin and for enabling skin sections between successive wrinkles to achieve prolonged contact with cosmetic and/or pharmaceutical substances carried by said device.

The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present invention consists of a method for prevention and/or treatment of skin irritation induced by depilation.

Skin care compositions and methods are provided comprising a highly hydrophobic substance, an alkaryl polyfluorocarbon, particularly a substituted phenyl-polyfluoroacylamino propanamide, an alkanol and refined oils and the oil triglyceride fractions in sufficient amount to provide substantial homogeneity. When employed for hirsutism, optionally antioxidants and moisturizer are added. For use against wrinkles, additionally vitamins, antioxidants and a mixture of extracts of naturally occurring substances are present.

The present invention relates to immunological cells that are useful in detecting changes in physiological states, which provide for methods of diagnosing diseases or monitoring the course of patient therapy. Also provided are arrays of antigen presenting cell-specific markers for detecting changes in physiological states, and methods of detecting such changes.

Procedure for the obtaining of genin and sapogenins extracts by enzymatic hydrolysis of kernels derived of the family Sapotaceae, genus Calocarpum, Chrysophyllum and Lucuma. The enzymes that catalyzes the hydrolysis are exogenous .beta.-glucosidases, of vegetable or microbial origin. The process uses mainly diverse kernel (seeds removed of the endocarp) derived but can also use the cyanogenic glycoside, lucumin and the related similar glycosides directly. It is also object of protection the process for the obtaining of these glycosides, starting of those kernels derived and the usage of these in the obtaining of genin and sapogenins and its uses in cosmetic and dermatologic compositions. The genin and sapogenins extracts are the main products used with these basic similar aims. The obtained genin extract are used in topical compositions to promote the opening of the pore facilitating the epithelial penetration or it can be used as flavouring or scent agent in foods or in alternating similar uses like in perfumery. The obtained sapogenins extract are used in topical compositions as astringent, defoliant, to favour oily skin penetration, to promote the renovation of the skin, to combat the epithelial aging, the growth of the hair or slow its fallen. The effect of oily skin penetration is enhanced synergised with a lipidic phase of the same Sapotaceae family. Besides the sapogenins have bacteriostatic and fungistatic activity in the compositions, in its topical use or in diverse preparations.

A double-stranded RNA, preferably a small, interfering (si)RNA or a siHybrid, to which cholesterol moieties are linked.

Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-.beta.-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.

Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1.alpha.-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1.alpha.,25-dihydroxyvitamin D.sub.3, 2-methylene-1.alpha.,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vi- tamin D.sub.3, 2-methylene-19-nor-(24R)-1.alpha.,25-dihydroxyvitamin D.sub.2, 2-methylene-(20R,25S)-19,26-dinor-1.alpha.,25-dihydroxyvitamin D.sub.3, 2-methylene-19-nor-1.alpha.-hydroxy-pregnacalciferol, 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1.alpha.-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1.alpha.-hydroxy-19-nor-bishomopregnacalcifero- l, 2-methylene-(20S)-23,23-difluoro-1.alpha.-hydroxy-19-nor-bishomopregnan- calciferol, (2-(3'hydroxypropyl-1',2'-idene)-19,23,24-trinor-(20S)-1.alpha.-hydroxyvi- tamin D.sub.3, 2-methylene-18,19-dinor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof. Compounds that activate retinoic acid receptors, such as retinoyls and retinoyl esters, include 13-cis-retinoic acid, all-trans-retinoic acid, (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexeneyl)nona-2,4,6,- 8-tetraenoic acid, 9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-napthoic acid, 4-[1-(3,5,5,8,8-pentamethyl-tetralin-2-yl)ethenyl]benzoic acid, retinobenzoic acid, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate, retinoyl t-butyrate, retinoyl pinacol, retinoyl cholesterol, an isomer thereof, a prodrug thereof for oral compositions, an ester thereof, a salt thereof, and/or, a solute thereof. Combinations of such active ingredients demonstrate synergistic efficacy.

The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I). These compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

An applicator cartridge for use with a device for electrokinetically delivering a medicament to a treatment site, the cartridge including: an applicator head including an active electrode, and a conductive path extending between a pair of electrical contacts, wherein the electrical contacts electrically engage respective contacts on the device when the cartridge is inserted into the device; a matrix support surface of said applicator head adjacent the active electrode; a matrix attached to the matrix support surface and in contact with the active electrode, the matrix having an exposed surface adapted to be applied to the treatment site; a medicament or a medicament and an electrically conductive carrier carried by said matrix; a removable lid covering the exposed surface of the matrix and sealed to the applicator head, the lid is conductively coupled to the applicator head and completes the conductive path on the applicator head, wherein removal of the lid breaks the conductive path.

Self-dissolving needle-like or filamentous shape percutaneously absorbable preparations, by which inherently poorly absorbable drugs into the body through the skin is efficiently administered. The preparations are made of at least one material selected from the group consisting of proteins, polysaccharides, polyvinyl alcohols, carboxyvinyl polymers and sodium polyacrylic acids. An active substance contained therein is released in a sustained-release fashion (1) by forming a water-insoluble layer on its surface, (2) by holding the active substance in porous materials, or (3) by imparting a long-acting characteristic to the active substance. The present invention also provides a sheet-like carrier for holding the preparations on at least one of the sides thereof, and a piece of equipment for holding the preparations so as to facilitate the administration of them.

A method and related compositions, including the use of N-acyl derivatives of sarcosine, provide for the delivery of bioactive agents through tissue surfaces such as the skin. The method and composition are particularly well suited for hydrophobic active agents such as serotonin (5HT.sub.3) receptor antagonists (e.g., ondansetron), antipsychotic agents (e.g., risperidone), benzodiazepines (e.g., flumazenil), and progestins (e.g., levonorgestrel).

An apparatus to monitor current density in the application of medicament to a treatment site of a mammalian user of a electrokinetic device including: an applicator cartridge including an active electrode, a matrix carrying a medicament or a medicament and an electrically conductive carrier; a device including an electrical power source connectable to the active electrode, a counter electrode, and an electronic circuit configured to control the application of electrical current through the active electrode to establish a conductive path extending from the power source, through the active electrode, matrix, the treatment site, the user and the counter electrode electrically connected to the power source, and an array of contacts monitoring current density flowing through the matrix and to the treatment site, wherein the array of sensors are arranged monitor the current density at various locations of the matrix and a contact area between the matrix and skin above the treatment site.

The invention relates to a cosmetic composition having a cooling effect, particularly a clear gel or a spray. The composition has a long-lasting cooling effect of about 8 hours and comprises a cooling complex consisting of 0.05-0.15% Menthyl Lactate, 0.1-0.2% Menthyl PCA and 0.05-0.2% Ethyl Menthane Carboxamide.

The invention relates to 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein identical or different R1, R2, R3 and R4 represent a hydrogen, fluoride, chloride or bromine atom, C1 to C12 linear or branched alkyl, C1 A C18 linear or branched hydroxy, alkoxy poly(ethoxy)-alkoxy with a C1 to C4 alkyl fragment and an ethoxy number ranging from 1 to 4, amino or mono or di-alkylamino with a C1 to C4 alkyl fragment group, X is ortho-, meta- or paraphenylene, 4,4'-biphenylene, 2,4- or 2,6- or 3,4- or 3,5-pyridinylene, 2,2'-bipyridinylene, meta- or paraphenylenediamino, ethylenediamine, 2,2'-piperazinylene, diacyl of formula -(R4CO)2-, wherein r represents a phenyl radical, a 3 to 10 carbon, phenanthrene or anthracene atoms alkyl chain except 1,4-bis(5,6-diphenyl-1,2,4-triazin-3-yl)benzene of 2,4-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine and of 2,6-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine, to cosmetic compositions containing said compounds and to the use thereof in the form of sun filters or light-protective agents.

Disclosed herein are cationic polymer nanocapsules encapsulating an oil-soluble active ingredient, and a cosmetic composition containing the same. The cationic polymer nanocapsules have a molecular weight of 5,000-100,000, a surface potential of 5-100 mV and a particle size of 50-500 nm. Also, disclosed is a cosmetic composition containing said cationic polymer nanocapsules.

The present invention relates to systems and methods using colorimetric indicators of oxidation in consumer products. In particular, betalains are used as oxidation indicators in food, pharmaceutical, and other products.

An article, preferably a patch, containing: a support in the form of at least one sheet containing fibres that are water-soluble at a temperature of 0-30.degree. C., and a composition carried by the support, containing at least one water-soluble gelling agent which swells in less than 30 seconds in water at a temperature of 20.degree. C. to 30.degree. C.

The present invention relates to novel chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating or preventing cancer.

This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.

In an aspect of the invention, an array of microprotrusions is formed by providing a mold with cavities corresponding to the negative of the microprotrusions, casting atop the mold a first solution comprising a biocompatible material and a solvent, removing the solvent, casting a second solution atop the first cast solution, removing the solvent from the second solution, and demolding the resulting array from the mold. The first solution preferably contains an active ingredient.

Various devices and methods for accessing and preparing treatment sites within the intervertebral disc space for subsequent negligible-incision surgical (NIS) or percutaneous procedures to treat disc degeneration and disc related back pain are disclosed. Also disclosed is a method for performing a percutaneous spine procedure including preparing a treatment site within the intervertebral disc space for subsequent delivery of a biomaterial to treat disc degeneration and disc related back pain.

The invention relates to a packages and kits for dispensing and/or administering pharmaceuticals, particularly for dispensing and/or administering combinations of different formulations.

The present invention relates to an application system for an active ingredient release system, comprising a film-form application strip, which is in each case bonded detachably to an active ingredient-containing plaster and a separate active ingredient release regulator separate there from.

The invention provides encapsulated, microparticulate active ingredient formulations for the controlled release of active ingredients on skin and skin appendages consisting of encapsulation material as casing and at least one enclosed biologically active ingredient as core, which is characterized in that enzymatically degradable organic hyperbranched polymers containing ester groups are used as encapsulation material.

The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the invention provides compositions and methods for the selection and purification of chiral compositions from racemic mixtures. In one aspect, the chimeric proteins and polymers (e.g., nanotubules, tubules, bundles, balls, fibers, filaments, sheets, threads, textiles) of the invention comprise a detectable moiety, e.g., a fluorescent protein. In one aspect, the invention provides a flame retardant or heat resistant device comprising a sheeting, a covering, a coating or an adhesive comprising a chimeric protein of the invention.

A moisturizing, cosmetic, or anti-wrinkle product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid or salt thereof has an average molecular weight in the range of 0.7-0.9 MDa, compositions comprising said product, and uses of said product.

The present invention comprises an antimicrobial composition. More particularly to an antimicrobial composition that comprises a. from about 0.01% to about 15% of at least one non-anionic surfactant, by weight of the composition; b. from about 0.01% to about 15% of at least one acid, by weight of the composition; c. from about 0% to about 99.85% of water, by weight of the composition; and wherein the composition is foaming.

This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed/treated hair so as to not affect the color of the hair.

A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or a human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

The invention relates to the use of at least one flavonoid having an uncharged flavan skeleton as synergist for enhancing the action of self-tanning substances, such as trioses and tetroses, in cosmetic and dermatological formulations and to corresponding novel compositions and to the preparation thereof.

The use of (a) hydroxydiphenyl ether compounds of formula wherein R.sub.1, R.sub.2 and R.sub.3 are each independently of the others hydrogen; hydroxy; C.sub.1-C.sub.20alkyl; hydroxy-substituted C.sub.1-C.sub.20alkyl; C.sub.5-C.sub.7cycloalkyl; C.sub.1-C.sub.20alkoxy; C.sub.1-C.sub.6alkylcarbonyl; phenyl; or phenyl-C.sub.1-C.sub.3alkyl; R.sub.4 is hydrogen, C.sub.1-C.sub.20alkyl; hydroxy-substituted C.sub.1-C.sub.20alkyl; C.sub.5-C.sub.7cycloalkyl; hydroxy; formyl; acetonyl; allyl; carboxy; carboxy-C.sub.1-C.sub.3alkyl; carboxyallyl; C.sub.2-C.sub.20alkenyl; C.sub.1-C.sub.6alkylcarbonyl; C.sub.1-C.sub.3alkylcarbonyl-C.sub.1-C.sub.3alkyl; phenyl; or phenyl-C.sub.1-C.sub.3alkyl; and R.sub.5 is hydrogen; C.sub.1-C.sub.20alkoxy; or C.sub.1-C.sub.6alkylcarbonyl;as melanogenesis inhibitors and for lightening the skin.

A cosmetic composition for caring for and/or making up the skin, lips and/or body in the form of a film, which is non-transferable, long-lasting with a comfortable feeling of use to consumers over long periods of wear time. The composition contains graftable POSS which forms a film when it cures in situ. The invention also relates to using such film for preparing a cosmetic composition and a makeup process and makeup kit comprising the product.

A gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles is described.

The present invention relates to a cosmetic composition intended for the care and/or make-up of keratinous substance(s) comprising, in a physiologically acceptable medium, at least one compound X, one compound Y and at least one catalyst, with at least one of the compounds X or Y being a polyorganosiloxane, and said compounds X and Y being capable of reacting together by a hydrosilylation reaction in the presence of a catalyst, with at least one compound from the compounds X and Y being present in said composition in an encapsulated form, said catalyst being combined with at least one of said encapsulated compound X or Y.

The present invention is directed to the use of a class of peptide compounds for treating non-inflammatory musculoskeletal pain or/and non-inflammatory osteoarthritic pain.

The present invention relates to a skin-care composition containing ginsenoside F1 and EGCG. More particularly, the present invention relates to an inhibitor of UV-induced apoptosis in epidermal cells showing an excellent skin-care effect by the synergistic interaction of the said ginsenoside F1 and EGCG even at low concentrations, and to a method for inhibiting apoptosis in epidermal cells.

A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.

Disclosed is a hydroxybenzamide derivative represented by the following Formula. A method for preparing the same and a cosmetic composition comprising the same are also disclosed. More particularly, the hydroxybenzamide derivative is obtained by reacting a hydroxybenzoic acid having a protecting group introduced thereto with a hydroxyphenyl amine to form a benzamide derivative and by hydrolyzing the benzamide derivative in an aqueous base solution to form a hydroxybenzamide derivative. The cosmetic composition comprising the hydroxybenzamide derivative as an active ingredient has excellent anti-oxidative, anti-aging and skin wrinkle-alleviating effects. wherein R1 represents a C1.about.C10 alkyl group, and n is an integer ranging from 1 to 3.

Disclosed is a joining element (10), especially a suture material for surgical use. Said joining element (10) is composed of a first material (12) that is essentially rigid during impingement by a relatively short-lasting tensile load on opposite sides as well as a second material (11) which is connected to the first material. The second material is substantially rigid during impingement by said tensile load on opposite sides while contracting slowly during a second period of time that is longer than the first period of time.

The present invention features methods of treating a patient having an epithelial lesion or disorder of impaired mucin function. The present invention further features methods of treating pain associated with epithelial lesions and disorders of impaired mucin function. Epithelial lesions and disorders of impaired mucin function can be treated using a pharmaceutical composition containing mucin glycoproteins in combination with therapeutic agents, e.g., trefoil polypeptides.

Sunscreen compositions are provided for protecting skin from sun-induced damage comprising (i) at least one UV-B or UV-A/UV-B sunblock active, (ii) at least one meroterpene and (iii) a dermatological acceptable carrier. Preferably, the sunblock active will be a UV-A/UV-B sunblock active or said sunscreen compositions will further comprise at least one UV-A sunblock active. Suitable meroterpenes include plant extracts having one or more meroterpene-enriched fractions, especially suited are Bakuchiol and derivatives of Bakuchiol. These skin protective compositions may optionally include an effective amount of one or more skin protective ingredients such as antioxidants, vitamins, anti-inflammatory agents, self-tanning agents and mixtures thereof.

The present invention relates to copolymers which comprise ethyl methacrylate, at least one .alpha.,.beta.-ethylenically unsaturated amide group-containing compound and at least one monoethylenically unsaturated carboxylic acid in copolymerized form, to cosmetic and pharmaceutical compositions which comprise at least one such copolymer, and to the use of these copolymers.

Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, and (c) water, wherein the composition has a pH of about 5 or less.

The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin, nail or mucosal membrane to which the composition is applied, and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition.

Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. A transdermal drug delivery system is provided for passive transdermal delivery of one or more ionizable active agents to a biological interface of a subject. A transdermal drug delivery system includes a backing substrate, and an active agent layer. The active layer includes a thickening agent, a plasticizer, and a therapeutically effective amount of an ionizable active agent.

A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of 1-1,000 micron, and a specific gravity of .gtoreq.1, not encapsulated within a film or a capsule-like enclosure, the particulate hydrophobic benefit agent comprising: a) a physically-modified form of the hydrophobic benefit agent; and b) a deposition-aid material bonded to the surface of the physically-modified benefit agent material, wherein the bonding between the two said materials is achieved prior to addition to i), wherein said deposition-aid material is not a surfactant having a weight average molecular weight of less than 5,000 Dalton.

This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.

14-O--[(((C.sub.1-6)Alkoxy-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]-mutil- ins, 14-O--[(((C.sub.1-6)Mono- or dialkylamino-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C.sub.1-8)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C.sub.0-5)-alkyl)-phenylsulfanyl)-acetyl]-mutilins 14-O-[((Guanidino-imino-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilin- s, 14-O-[((Ureido-imino-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins- , 14-O-[((Thioureido-imino-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]-mutil- ins, 14-O-[((Isothioureido-imino-(C.sub.1-6)alkyl)-phenylsulfanyl)-acetyl]- -mutilins and their use as pharmaceuticals.

The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

A method and composition for the transdermal administration of proton pump inhibitors such as substituted pyridyl methylsulfinyl benzimidazoles, and in particular, omeprazole, lansoprazole, esomeprazole, pantoprazole and raberprazole. The method and composition include the use of a hydroxide-releasing agent as a permeation enhancer to increase the flux of the protein pump inhibitor through a patient's skin or mucosal tissues and optionally also include the use of a carrier such as 1,3-butanediol, dipropylene glycol, and hexylene glycol.

The object of the invention is a process for obtaining an active ingredient for increasing the mechanical strength of the skin, wherein the process utilizes the following steps: Solubilization of rye fibers and/or seeds and/or bran in water, Simultaneous or successive enzymatic hydrolysis or hydrolyses, Separation of soluble and insoluble phases by filtration, centrifuging, decanting, Treatment of the active fraction, and Sterilizing filtration.The product obtained by the process, cosmetic compositions containing the product, and method of using the product are also disclosed.

Described is a device and method for administration of molecules to tissue in vivo for various medical applications, the device comprising a single-needle electrode which provides for the ability, when the needle is inserted into tissue, such as skin or muscle, to pulse tissue with a non-uniform electric field sufficient to cause reversible poration of cells lying along or in close proximity to the track made by the needle upon its insertion into said tissue

A method of treating a patient with a microneedle array having an active agent disposed on at least a portion of one or more of the microneedles, wherein the array with active agent is characterized by a first optical response when probed with a selected incident light spectrum. The array with active agent is applied to a skin surface, optionally allowed to remain on the skin surface for a specified time, and removed. The used array is probed with the selected incident light spectrum, a second optical response is sensed, and the difference between the first optical response and the second optical response is determined and compared to a predetermined threshold value.

An image processing technique includes acquiring a main image of a scene and determining one or more facial regions in the main image. The facial regions are analysed to determine if any of the facial regions includes a defect. A sequence of relatively low resolution images nominally of the same scene is also acquired. One or more sets of low resolution facial regions in the sequence of low resolution images are determined and analysed for defects. Defect free facial regions of a set are combined to provide a high quality defect free facial region. At least a portion of any defective facial regions of the main image are corrected with image information from a corresponding high quality defect free facial region.

A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent; and an Accommodating Agent or Complex; and methods of treatment. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent.

A compound of formula (I): is claimedwherein A represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; R.sup.1 represents phenyl, pyridyl or thienyl wherein the phenyl group may be optionally substituted by one or two groups independently selected from fluorine, cyano, --C(O)OCH.sub.3 and --C(O)OCH.sub.2CH.sub.3, and the pyridyl group may be optionally substituted by one fluorine group; and R.sup.2 represents methyl or ethyl; along with physiologically functional derivatives thereof, pharmaceutical compositions and formulations thereof, combinations thereof, methods of treatment employing such compounds and processes for preparing the compounds.

The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway.

A water-free composition, in particular a cosmetic composition, in the form of a pencil with a cast or extruded lead or a workable paste which is suitable for cosmetic uses, in particular in the field of decorative cosmetics, for coloring, improving the appearance of and caring for keratinic materials such as for example the skin, semi-mucous membranes and mucous membranes, eyelashes, eyebrows and the hair. That preparation includes a specifically matched combination of water-soluble and lipid-soluble active substances in the form of a so-called "active substance cocktail". The production and use of that composition are also described.

A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.

The present invention provides novel intradermal vaccines and novel uses for adjuvants in the preparation of intradermal vaccines, and also novel methods of treatment comprising them. The intradermal adjuvants, and methods, of the present invention comprise a saponin and a sterol, wherein the saponin and sterol are formulated in a liposome. The intradermal adjuvants are used in the manufacture of intradermal vaccines for humans, and in the intradermal treatment of humans.

The invention provides novel coated metal oxide particles, wherein metal oxide particles are coated with a sunscreen on a polysiloxane basis with UV-A and/or UV-B and/or UV-C and/or broadband filter activity and a process for producing coated metal oxide particles and their use especially in cosmetic or dermatological formulations for the protection against harmful effects of sunlight.

Compositions and methods for treatment of dermal scarring and wrinkling, by application to the skin of a cosmetically effective amount of Plantago major or Plantago Lanceolata. The plantain may be utilized in powdered form in an aqueous paste or poultice, or in a creme base or ointment that is applied to the skin for various periods of time from 1 to 10 hours at a frequency of 1-12 times per week, for a period of 3-50 weeks or more. The composition is effective to remediate dermal scarring and wrinkling, and at least partially restore skin to an undamaged, undeteriorated state.

The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I). These compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.

A silicone adhesive composition used for adhering a device or a substance to a wet surface contains (i) a silicone resin that is cohydrolysis product of a trialkyl hydrolyzable silane and an alkyl silicate in which the cohydrolysis product contains a plurality of silicon-bonded hydroxy groups; (ii) a linear organopolysiloxane fluid containing terminal silicon-bonded hydroxy groups having a viscosity above 200,000 mm.sup.2/.sub.s at 25.degree. C.; (iii) a trialkylsiloxy terminated polyorganosiloxane fluid having a viscosity of 100,000-600,000 mm.sup.2/.sub.s at 25.degree. C.; (iv) a water soluble muco-adhesive polymer selected from the group consisting of a poly(ethylene oxide) polymer having a molecular weight of 100,000 to 8,000,000, an acrylic acid polymer having a molecular weight of 500,000 to 4,500,000,000, and a hydroxyethylcellulose polymer having a molecular weight of 90,000 to 1,300,000,000; and optionally, (v) a solvent selected from the group consisting of aliphatic hydrocarbons, aromatic hydrocarbons, esters, volatile linear and cyclic silicone compounds. Other components such as a silicone polyether, a silicone wax, a drug, an excipient, and/or an active ingredient can also be included.

The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.

The invention relates to the use of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein cycle penetrating bonds display an ortho, meta or para indifferent substitution position, identical or different R.sub.1 and R.sub.2 represent a hydrogen, fluoride, chloride or bromine atom, C.sub.1 to C.sub.12 linear or branched alkyl, C.sub.1 A C.sub.18 linear or branched hydroxy, alkoxy poly(ethoxy)-alkoxy with a C.sub.1 to C.sub.4 alkyl fragment and an ethoxy number ranging from 1 to 4, amino or mono or di-alkylamino with a C.sub.1 to C.sub.4 alkyl fragment group, R.sub.3 represents a chlorine atom, a hydroxy, amino, a phenyl possibly 1 to 3 times substituted by a hydroxy radical situated at least in a para or phenyl position possibly 1 to 3 times substituted in an ortho, meta or para position by a C.sub.1 to C.sub.12 alkoxy or cyano or alkymino group with a C.sub.1 to C.sub.7 alkyl fragment in the form of active sun filters or light-protective agents and to cosmetic composition containing said compounds.

This invention relates to a method for preparing dispersions of solid particles, especially pigments, metal oxides and mineral fillers in organic media, to dispersing compositions used in this method and to dispersions containing these dispersion compositions. The dispersing compositions include an oil soluble surfactant selected from the group consisting of phospholipids, alkyl acids, nonionic surfactants having an HLB less than 10, and mixtures thereof; either an anhydride based polymer selected from the group consisting of polyalkene succinic anhydrides; maleinized polyisoprene; maleinized polybutadiene; maleinized copolymers of isoprene and butadiene; copolymers of styrene and maleic anhydride; derivatives formed by reaction of the anhydride group of the anhydride based polymer with one or more of water, amines, alcohols, and polyols; and mixtures thereof; or a mixture of the said anhydride based polymer with polyhydroxystearic acid; and optionally a liquid oil carrier.

Described is the use of a combination of an oxocarboxylic acid with metal ions, organic bases or polymers substantive for keratin material for combating, suppressing or eliminating odors of the hair of skin. Preferred oxocarboxylic acids are those of general formula R--C(.dbd.O)--A--CO.sub.2H wherein R stands for hydrogen or a monovalent organic group and A strands for a divalent organic group or for a single bond. A preferred combination is zinc levulinate which can be used, in particular, for combating the unpleasant odors of sulfur compounds, for example after permanent wave treatments.

A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R' may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU', UCO2U', CO2U, UCO2COU, CO2H, UCO2H, COX, UCOX, UCO2 R', CO2COU, Aryl, ArylU, ArylUU, ArylUU'U'', NH2, UNH2, NHU, NUU', NO2, UNO2, UCONH2, CONH2, UCONHU', CONHU, UCONU'U'', CONU'U'', halogen, PO4H3, PO4H3-z, PO4H3-zU (z = 0, 1, 2 or 3), PU3, P U'U''U'''SH, SO2 and SO3H; wherein U, U', U'' and U''' may be independently selected from any alkyl, alkenyl or alkynyl group where the number of carbon atoms is between 1 and 31; wherein X=halogen; wherein y=1-100; provided that Q, R and R' can not all be C1 alkyl; and wherein the compound of formula (I) is present in an amount of at least 1% of the composition.

The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one fatty compound, capable of forming a liquid crystal; (c) at least one thickening agent; (d) at least one active agent; and (e) water. Also disclosed is a method of treating skin with the above-disclosed skin care composition.

The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one thickening agent; (c) at least one primary emulsifier chosen from a water-in-silicone emulsifier; (d) at least one non-emulsifying silicone elastomer; (e) at least one active agent; and (f) water. Also disclosed is a method of treating skin with the above-disclosed skin care composition.

It is an object of the present invention to provide an anti-acne skin agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size, moisturizing properties, and high permeability into skin. The present invention provides an anti-acne skin agent for external use, which comprises protein nanoparticles containing an active ingredient.

The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component,wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.

Formulations of viral vectors for topical application are disclosed as well as methods for making the same. Also disclosed are methods of treating a subject or diagnosing disease in a subject using the formulations of the present invention.

A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25.degree. C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.

Compositions, including those in which the active ingredient or agent is stable and capable of penetrating the sites of topical application are provided. The compositions can include a macromolecule, for example, a parathyroid hormone (PTH), a PTH-like hypercalcemic factor (CFF) or biologically active variant of a PTH or CFF in a vehicle comprising a polymer or cationic liposome. The compositions can also include other substances that further promote the stability of the active agent (e.g., buffers, antioxidants or carbohydrates). Also provided are methods for using the compositions for treatment of skin disorders (e.g., hyperproliferative skin disorders, including, but not limited to, for example, psoriasis, acne, rosacea or acne.)

Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C.sub.1-C.sub.22alkyl; C.sub.1-C.sub.22alkylthio; C.sub.2-C.sub.22alkylthioalkyl; C.sub.5-C.sub.7cycloalkyl; phenyl; C.sub.7-C.sub.9phenylalkyl; or SO.sub.3M; G.sub.2 is C.sub.1-C.sub.22alkyl; C.sub.5-C.sub.7cycloalkyl; phenyl; or C.sub.7-C.sub.9phenylalkyl; E is oxyl or hydroxyl; V is --O--; or --NH--; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G.sub.3 are as defined in claim 1; G.sub.4 and G.sub.5 are each independently of the other hydrogen; or C.sub.1-C.sub.22alkyl; exhibit marked antiinflammatory action.

The invention relates to a cosmetic composition for application to the skin, having: a) 0.05 to 0.5% by weight of a quaternized polysaccharide, 0.05 to 5.0% by weight of a polyethylene glycol derivative or polypropylene glycol derivative and/or 0.05 to 3% by weight of a polymeric quaternized ammonium compound ("polyquaternium"), b) 10 to 40% by weight of oils and/or oil-like constituents, and c) 0.2 to 15% by weight of an ester quat and/or of a dialkyl quat.

Photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane compound UV-A sunscreen and at least one merocyanine sulfone compound.

Stable, topically applicable cosmetic/pharmaceutical skin depigmenting compositions contain at least one phenolic compound, at least one retinoid and at least one corticoid, and are formulated as aqueous-alcoholic gels in topically applicable, physiologically acceptable media therefor.

The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.

Disclosed are compounds having Formula I: and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, A, and B are as defined herein, for use in methods for treating, preventing or ameliorating hyperproliferative disorders, such as cancer and other diseases and conditions. The invention also relates to pharmaceutical compositions and formulations comprising a compound having Formula I, and in combination with one or more other active agents and/or treatments.

A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances. The amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit. The oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber. The biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management.

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or PRO1480 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

The present invention provides agents for regulating the activity of interferon-producing cells (IPCs), which comprise as active ingredients antibodies that bind to BST2 and/or to its homologues, and methods for regulating IPC activity that use these antibodies. According to the present invention, the ability of IPCs to produce interferons (IFNs) and the number of cells can be directly regulated. The present invention also provides uses of BST2 and/or its homologues as markers for IPC activation. Compounds that regulate IPC activation can be screened using the markers for IPC activation.

A transdermal medicament patch includes a biocompatible substrate having a therapeutic face on one side configured for disposition against the skin of a patient, a biocompatible adhesive on the therapeutic face, a planar medicament matrix covering a portion of the therapeutic face, and a release liner covering the portion of therapeutic that is not obscured by the medicament matrix. An aperture formed through the release sheet affords direct access by medicament to the entire surface of the medicament matrix opposite from the therapeutic face of the substrate. An active electrode positioned between the medicament matrix and the therapeutic face of the substrate includes an electrically conductive backing layer positioned against the therapeutic face of the substrate and a pH-control layer covering less than all of the side of the backing layer opposite from the therapeutic face of the substrate. One active electrode design criterion relates the relative size of the pH-control layer to the size of the backing layer; another relates the size of portion of the area of the backing layer that is free of the pH-control lawyer to the size of the pH-control layer. The pH-control layer is made of an electrically conductive material capable of moderating changes in the hydrogen-ion concentration in the medicament matrix during iontophoretic current flow. An electrical contact electrically coupled through the substrate to the backing layer includes a hollow, electrically conductive snap fitting having an open end and a cooperating stud that is inserted into the open end of the snap.

A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

A cosmetic composition suitable for topical application to human or animal skin comprising an effective amount of active ingredient dispersed in an acceptable cosmetic base or carrier, wherein the active ingredient comprises a mixture of an amino acid, a low glycemic glycoside and a Vitamin, wherein the amino acid is L-arginine, and wherein the low glycemic glycoside is derived from kiwi fruit.

Transdermal delivery peptides for the treatment of skin diseases and/or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic acids, expression vectors, and methods of their use, which encode the transdermal delivery peptides are disclosed. Methods are also provided for in vivo phage display for identifying further peptides with enhanced transdermal delivery capability.

The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.

There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.

Foaming compositions having high solvent content and compositions for foaming high solvent content formulations are disclosed having a fluorinated phosphate ester surfactant ("FPES") of the formula (R.sup.a--O).sub.x--P(O)--(OR.sup.b).sub.y in combination with a fluorinated alcohol ("FA") of the formula R.sup.cOH, where x is 1 to 3, y is (3-x), R.sup.a is a group R.sup.1-R.sup.2- with R.sup.1 being a fluorinated C.sub.6-18hydrocarbon optionally interrupted by groups of one or two non-fluorinated (or less fluorinated) carbons per interruption, and/or optionally interrupted by heteroatoms or functional groups, and R.sup.b is selected from H and positively charged amines, and R.sup.c is the same or different as R.sup.a and if different is selected from the same group of R.sup.a materials as well as from analogous groups to R.sup.a except that they have only 1-3 carbons in the R.sup.1 portion of R.sup.a instead of the R.sup.a requirement of at least 4 carbons. The ratio of FA to FPES is at least 5% FA to not more than 95% FPES based on the total FA+FPES weight. The compositions are especially useful for foaming high organic solvent content (>20% by weight solvent) with the solvent being selected from lower aliphatic alcohol, C.sub.5-6cyclic saturated or unsaturated alcohols, lower alkyl-C(O)-lower alkyl, lower alkyl-O--C(O)-lower alkyl, lower alkylene glycols, and lower alkylene glycol-mono lower alkyl ethers.

A skin whitening composition and a method for the same are provided. The skin whitening composition comprises a far-infrared ray releasing substance having a primary component of an oxide mineral, wherein the skin whitening composition achieves a whitening effect via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of administering a far-infrared ray releasing substance to a subject and reducing melanogenesis of the subject by inhibiting growth of a pigment cell, wherein the far-infrared releasing substance has an oxide mineral.

It is an object of our invention to provide capsule particles and a method of crea